1. Patent Search
  2. Details

METHODS AND COMPOSITIONS FOR ANAEROBIC BACTERIAL FERMENTATION

20220364044 · 2022-11-17

    Inventors

    Cpc classification

    International classification

    Abstract

    Provided herein are methods and compositions related to fermentation of anaerobic bacteria.

    Claims

    1. A method of culturing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor under an anaerobic atmosphere comprising greater than 1% CO.sub.2.

    2. The method of claim 1, wherein the anaerobic atmosphere comprises at least 8% CO.sub.2.

    3. The method of claim 1 or claim 2, wherein the anaerobic atmosphere comprises at least 20% CO.sub.2.

    4. The method of claim 1, wherein the anaerobic atmosphere comprises from 8% to 40% CO.sub.2.

    5. The method of claim 1, wherein the anaerobic atmosphere comprises from 20% to 30% CO.sub.2.

    6. The method of claim 1, wherein the anaerobic atmosphere comprises about 25% CO.sub.2.

    7. The method of any one of claims 1-6, wherein the anaerobic atmosphere consists essentially of CO.sub.2 and N.sub.2.

    8. The method of claim 1 wherein the anaerobic atmosphere comprises about 25% CO.sub.2 and about 75% N.sub.2.

    9. A method of culturing anaerobic bacteria, the method comprising the steps of a) purging a bioreactor with an anaerobic gas mixture comprising greater than 1% CO.sub.2; and b) culturing the anaerobic bacteria in the bioreactor purged in step a).

    10. The method of claim 9, wherein the anaerobic gas mixture comprises at least 8% CO.sub.2.

    11. The method of claim 9 or claim 10, wherein the anaerobic gas mixture comprises at least 20% CO.sub.2.

    12. The method of claim 9, wherein the anaerobic gas mixture comprises from 8% to 40% CO.sub.2.

    13. The method of claim 9, wherein the anaerobic gas mixture comprises from 20% to 30% CO.sub.2.

    14. The method of claim 9, wherein the anaerobic gas mixture comprises about 25% CO.sub.2.

    15. The method of claim 9, wherein the anaerobic gas mixture comprises about 100% CO.sub.2.

    16. The method of any one of claims 9-15, wherein the anaerobic gas mixture consists essentially of CO.sub.2 and N.sub.2.

    17. The method of claim 9, wherein the anaerobic gas mixture comprises about 25% CO.sub.2 and about 75% N.sub.2.

    18. The method of any one of claims claim 9-17, wherein the method further comprises the step of inoculating a growth media with anaerobic bacteria, wherein the inoculation step precedes step b).

    19. The method of claim 18, wherein the volume of anaerobic bacteria is about 0.1% v/v of the growth media.

    20. The method of claim 19, wherein the growth media is about 1 L in volume.

    21. The method of any one of claims 19-20, wherein the volume of anaerobic bacteria is about 1 mL.

    22. The method of any one of claims 9-21, wherein the anaerobic bacteria is cultured for 10-24 hours.

    23. The method of claim 22, wherein the anaerobic bacteria is cultured for 14 to 16 hours.

    24. The method of any one of claims 22-23, wherein the method further comprises the step of inoculating about 5% v/v of the cultured bacteria in a growth media.

    25. The method of claim 24, wherein the growth media is about 20 L in volume.

    26. The method of any one of claims 24-25, wherein the anaerobic bacteria is cultured for 10-24 hours.

    27. The method of claim 26, wherein the anaerobic bacteria is cultured for 12 to 14 hours.

    28. The method of any one of claims 26-27, wherein the method further comprises the step of inoculating about 0.5% v/v of the cultured bacteria in a growth media.

    29. The method of claim 28, wherein the growth media is about 3500 L in volume.

    30. The method of any one of claims 28-29, wherein the anaerobic bacteria is cultured for 10-24 hours.

    31. The method of claim 30, wherein the anaerobic bacteria is cultured for 12 to 14 hours.

    32. The method of any one of claims 18-31, wherein the growth media comprises yeast extract, soy peptone A2SC 19649, Soy peptone E110 19885, dipotassium phosphate, monopotassium phosphate, L-cysteine-HCl, ammonium chloride, maltodextrin, glucose, and hemoglobin.

    33. The method of claim 32, wherein the growth media comprises 5 g/L to 15 g/L yeast extract 19512.

    34. The method of claim 32, wherein the growth media comprises 10 g/L yeast extract 19512.

    35. The method of any one of claims 32-34, wherein the growth media comprises 10 g/L to 15 g/L soy peptone A2SC 19649

    36. The method of claim 35, wherein the growth media comprises 12.5 g/L soy peptone A2SC 19649.

    37. The method of any one of claims 32-36, wherein the growth media comprises 10 g/L to 15 g/L Soy peptone E110 19885.

    38. The method of claim 37, wherein the growth media comprises 12.5 g/L Soy peptone E110 19885.

    39. The method of any one of claims 32-38, wherein the growth media comprises 1 g/L to 2 g/L dipotassium phosphate.

    40. The method of claim 39, wherein the growth media comprises 1.59 g/L Dipotassium phosphate.

    41. The method of any one of claims 32-40, wherein the growth media comprises 0.5 g/L to 1.5 g/L monopotassium phosphate.

    42. The method of claim 41, wherein the growth media comprises 0.91 g/L monopotassium phosphate.

    43. The method of any one of claims 32-42, wherein the growth media comprises 0.1 g/L to 1.0 g/L L-cysteine-HCl.

    44. The method of claim 43, wherein the growth media comprises 0.5 g/L L-cysteine-HCl.

    45. The method of any one of claims 32-44, wherein the growth media comprises 0.1 g/L to 1.0 g/L ammonium chloride.

    46. The method of claim 45, wherein the growth media comprises 0.5 g/L ammonium chloride.

    47. The method of any one of claims 32-46, wherein the growth media comprises 20 g/L to 30 g/L maltodextrin.

    48. The method of claim 47, wherein the growth media comprises 25 g/L maltodextrin.

    49. The method of any one of claims 32-48, wherein the growth media comprises 5 g/L to 15 g/L glucose.

    50. The method of claim 49, wherein the growth media comprises 10 g/L glucose.

    51. The method of any one of claims 32-50, wherein the growth media comprises 0.01 g/L to 0.05 g/L hemoglobin.

    52. The method of claim 51, wherein the growth media comprises 0.02 g/L hemoglobin.

    53. The method of any one of claims 9-52, wherein the anaerobic bacteria is cultured at a temperature of 35° C. to 42° C.

    54. The method of claim 53, wherein the anaerobic bacteria is cultured at a temperature of 37° C.

    55. The method of any one of claims 9-54, wherein the anaerobic bacteria is cultured at a pH of 5.5 to 7.5.

    56. The method of claim 55, wherein the anaerobic bacteria is cultured at a pH of 6.5.

    57. The method of any one of claims 9-56, wherein culturing the anaerobic bacteria comprises agitating at a RPM of 50 to 300.

    58. The method of claim 57, wherein the anaerobic bacteria is agitated at a RPM of 150.

    59. The method of any one of claims 9-58, wherein the anaerobic gas mixture is continuously added during culturing.

    60. The method of claim 59, wherein the anaerobic gas mixture is added at a rate of 0.002 vvm to 0.02 vvm.

    61. The method of any one of claims 9-58, wherein CO.sub.2 is continuously added during culturing.

    62. The method of claim 61, wherein the CO.sub.2 is added at a rate of 0.002 vvm to 0.1 vvm.

    63. The method of claim 61, wherein the CO.sub.2 is added at a rate of 0.007 vvm.

    64. The method of claim 61, wherein the CO.sub.2 is added at a rate of 0.1 vvm.

    65. The method of any one of claims 9-64, wherein the method further comprising the step of harvesting the cultured bacteria when a stationary phase is reached.

    66. The method of claim 65, further comprising the step of centrifuging the cultured bacteria after harvesting to produce a cell paste.

    67. The method of claim 66, further comprising diluting the cell paste with a stabilizer solution to produce a cell slurry.

    68. The method of claim 67, further comprising the step of lyophilizing the cell slurry to produce a powder.

    69. The method of claim 68, further comprising irradiating the powder with gamma radiation.

    70. The method of any one of claims 1-69, wherein the anaerobic bacteria are selected from bacteria of the genus Actinomyces, Bacteroides, Clostridium, Fusobacterium, Peptostreptococcus, Porphyromonas, Prevotella, Propionibacterium, or Veillonella.

    71. The method of any one of claims 1-69, wherein the anaerobic bacteria are from a strain of Prevotella bacteria comprising one or more proteins listed in Table 1.

    72. The method of any one of claims 1-69, wherein the anaerobic bacteria are from a strain of Prevotella substantially free of a protein listed in Table 2.

    73. The method of any one of claims 1-69, wherein the anaerobic bacteria are from a strain of Prevotella bacteria comprising one or more of the proteins listed in Table 1 and is free or substantially free of a protein listed in Table 2.

    74. The method of any one of claims 1-73, wherein the anaerobic bacteria are Prevotella albensis, Prevotella amnii, Prevotella bergensis, Prevotella bivia, Prevotella brevis, Prevotella bryantii, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella histicola, Prevotella intermedia, Prevotella maculosa, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nigrescens, Prevotella oralis, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella salivae, Prevotella stercorea, Prevotella tannerae, Prevotella timonensis, Prevotella jejuni, Prevotella aurantiaca, Prevotella baroniae, Prevotella colorans, Prevotella corporis, Prevotella dentasini, Prevotella enoeca, Prevotella falsenii, Prevotella fusca, Prevotella heparinolytica, Prevotella loescheii, Prevotella multisaccharivorax, Prevotella nanceiensis, Prevotella oryzae, Prevotella paludivivens, Prevotella pleuritidis, Prevotella ruminicola, Prevotella saccharolytica, Prevotella scopos, Prevotella shahii, Prevotella zoogleoformans, or Prevotella veroralis.

    75. A bioreactor comprising anaerobic bacteria under an anaerobic atmosphere comprising at least about 1% CO.sub.2.

    76. The bioreactor of claim 75, wherein the anaerobic atmosphere comprises at least 8% CO.sub.2.

    77. The bioreactor of claim 75 or claim 76, wherein the anaerobic atmosphere comprises at least 20% CO.sub.2.

    78. The bioreactor of claim 75, wherein the anaerobic atmosphere comprises from 8% to 40% CO.sub.2.

    79. The bioreactor of claim 75, wherein the anaerobic atmosphere comprises from 20% to 30% CO.sub.2.

    80. The bioreactor of claim 75, wherein the anaerobic atmosphere comprises about 25% CO.sub.2.

    81. The bioreactor of any one of claims 75-80, wherein the anaerobic atmosphere consists essentially of CO.sub.2 and N.sub.2.

    82. The bioreactor of claim 75, wherein the anaerobic atmosphere comprises about 25% CO.sub.2 and about 75% N.sub.2.

    83. The bioreactor of any one of claims claim 75-82, wherein bioreactor is 1 L, 20 L, 3500 L 20,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L, 400,000 L or 500,000 L.

    84. The bioreactor of any one of claims 75-83, wherein the bioreactor further comprises a growth media.

    85. The bioreactor of claim 84, wherein the growth media comprises yeast extract, soy peptone A2SC 19649, Soy peptone E110 19885, dipotassium phosphate, monopotassium phosphate, L-cysteine-HCl, ammonium chloride, glucidex 21 D, glucose, and hemoglobin.

    86. The bioreactor of claim 85, wherein the growth media comprises 5 g/L to 15 g/L yeast extract 19512.

    87. The bioreactor of claim 85 or claim 86, wherein the growth media comprises 10 g/L yeast extract 19512.

    88. The bioreactor of any one of claims 85-87, wherein the growth media comprises 10 g/L to 15 g/L soy peptone A2SC 19649

    89. The bioreactor of claim 88, wherein the growth media comprises 12.5 g/L soy peptone A2SC 19649.

    90. The bioreactor of any one of claims 85-89, wherein the growth media comprises 10 g/L to 15 g/L Soy peptone E110 19885.

    91. The bioreactor of claim 90, wherein the growth media comprises 12.5 g/L Soy peptone E110 19885.

    92. The bioreactor of any one of claims 85-91, wherein the growth media comprises 1 g/L to 2 g/L dipotassium phosphate.

    93. The bioreactor of claim 92, wherein the growth media comprises 1.59 g/L dipotassium phosphate.

    94. The bioreactor of any one of claims 85-93, wherein the growth media comprises 0.5 g/L to 1.5 g/L monopotassium phosphate.

    95. The bioreactor of claim 94, wherein the growth media comprises 0.91 g/L monopotassium phosphate.

    96. The bioreactor of any one of claims 85-95, wherein the growth media comprises 0.1 g/L to 1.0 g/L L-cysteine-HCl.

    97. The bioreactor of claim 96, wherein the growth media comprises 0.5 g/L L-cysteine-HCl.

    98. The bioreactor of any one of claims 85-97, wherein the growth media comprises 0.1 g/L to 1.0 g/L ammonium chloride.

    99. The bioreactor of claim 98, wherein the growth media comprises 0.5 g/L ammonium chloride.

    100. The bioreactor of any one of claims 85-99, wherein the growth media comprises 20 g/L to 30 g/L glucidex 21 D.

    101. The bioreactor of claim 100, wherein the growth media comprises 25 g/L glucidex 21 D.

    102. The bioreactor of any one of claims 85-101, wherein the growth media comprises 15 g/L to 15 g/L glucose.

    103. The bioreactor of claim 102, wherein the growth media comprises 10 g/L glucose.

    104. The bioreactor of any one of claims 85-103, wherein the growth media comprises 0.01 g/L to 0.05 g/L hemoglobin.

    105. The bioreactor of claim 104, wherein the growth media comprises 0.02 g/L hemoglobin.

    106. The bioreactor of any one of claims 75-105, wherein the bioreactor is at a temperature of 35° C. to 42° C.

    107. The bioreactor of claim 106, wherein the bioreactor is at a temperature of 37° C.

    108. The bioreactor of any one of claims 85-107, wherein the growth media is at a pH of 5.5 to 7.5.

    109. The method of claim 108, wherein the growth media is at a pH of 6.5.

    110. The bioreactor of any one of claims 75-109, wherein the anaerobic bacteria are selected from bacteria of the genus Actinomyces, Bacteroides, Clostridium, Fusobacterium, Peptostreptococcus, Porphyromonas, Prevotella, Propionibacterium, or Veillonella.

    111. The bioreactor of any one of claims 75-109, wherein the anaerobic bacteria are from a strain of Prevotella bacteria comprising one or more proteins listed in Table 1.

    112. The bioreactor of any one of claims 75-109, wherein the anaerobic bacteria are from a strain of Prevotella substantially free of a protein listed in Table 2.

    113. The bioreactor of any one of claims 75-109, wherein the anaerobic bacteria are from a strain of Prevotella bacteria comprising one or more of the proteins listed in Table 1 and is free or substantially free of a protein listed in Table 2.

    114. The bioreactor of any one of claims 75-109, wherein the anaerobic bacteria are Prevotella albensis, Prevotella amnii, Prevotella bergensis, Prevotella bivia, Prevotella brevis, Prevotella bryantii, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella histicola, Prevotella intermedia, Prevotella maculosa, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nigrescens, Prevotella oralis, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella salivae, Prevotella stercorea, Prevotella tannerae, Prevotella timonensis, Prevotella jejuni, Prevotella aurantiaca, Prevotella baroniae, Prevotella colorans, Prevotella corporis, Prevotella dentasini, Prevotella enoeca, Prevotella falsenii, Prevotella fusca, Prevotella heparinolytica, Prevotella loescheii, Prevotella multisaccharivorax, Prevotella nanceiensis, Prevotella oryzae, Prevotella paludivivens, Prevotella pleuritidis, Prevotella ruminicola, Prevotella saccharolytica, Prevotella scopos, Prevotella shahii, Prevotella zoogleoformans, or Prevotella veroralis.

    115. A method of culturing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor into which a gas mixture comprising greater than 1% CO.sub.2 is added.

    116. The method of claim 115, wherein the gas mixture comprises at least 8% CO.sub.2.

    117. The method of claim 115 or claim 116, wherein the gas mixture comprises at least 20% CO.sub.2.

    118. The method of claim 115, wherein the gas mixture comprises from 8% to 40% CO.sub.2.

    119. The method of claim 115, wherein the gas mixture comprises from 20% to 30% CO.sub.2.

    120. The method of claim 115, wherein the gas mixture comprises about 25% CO.sub.2.

    121. The method of any one of claims 115-120, wherein the gas mixture consists essentially of CO.sub.2 and N.sub.2.

    122. The method of claim 115 wherein the gas mixture comprises about 25% CO.sub.2 and about 75% N.sub.2.

    Description

    BRIEF DESCRIPTION OF THE FIGURES

    [0046] FIG. 1 is a schematic of an exemplary manufacturing process for anaerobic bacteria, including, e.g., Prevotella histicola.

    [0047] FIG. 2 is a schematic of an exemplary manufacturing process described herein.

    [0048] FIG. 3 is a plot showing that reduced rates of sparging (bubbling) of 95% N.sub.2, 5% CO.sub.2 gas (0.1 vvm vs. 0.02 vvm) results in decreased growth potential of Prevotella histicola Strain B 50329 anaerobic bacteria. (vvm stands for Volume of gas per Volume of vessel per Minute).

    [0049] FIG. 4 is a plot showing that the presence of CO.sub.2 is necessary for initiating Prevotella histicola Strain B 50329 growth, as well as the effect of various amounts of CO.sub.2 (0%, 5%, 25%, 100%) on Prevotella histicola growth potential. (vvm stands for volume of gas per volume of vessel per minute).

    [0050] FIG. 5 is a plot showing that Prevotella histicola Strain B 50329 consumes CO.sub.2.

    [0051] FIG. 6 is a plot showing that maltodextrin in combination with glucose can support growth of Prevotella histicola Strain B 50329 better than glucose alone.

    DETAILED DESCRIPTION

    Definitions

    [0052] As used herein, “anaerobic conditions” are conditions with reduced levels of oxygen compared to normal atmospheric conditions. For example, in some embodiments anaerobic conditions are conditions wherein the oxygen levels are partial pressure of oxygen (pO.sub.2) no more than 8%. In some instances, anaerobic conditions are conditions wherein the pO.sub.2 is no more than 2%. In some instances, anaerobic conditions are conditions wherein the pO.sub.2 is no more than 0.5%. In certain embodiments, anaerobic conditions may be achieved by purging a bioreactor and/or a culture flask with a gas other than oxygen such as, for example, nitrogen and/or carbon dioxide (CO.sub.2).

    [0053] The term “decrease” or “deplete” means a change, such that the difference is, depending on circumstances, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1/100, 1/1000, 1/10,000, 1/100,000, 1/1,000,000 or undetectable after treatment when compared to a pre-treatment state.

    [0054] As used herein, “engineered bacteria” are any bacteria that have been genetically altered from their natural state by human intervention and the progeny of any such bacteria. Engineered bacteria include, for example, the products of targeted genetic modification, the products of random mutagenesis screens and the products of directed evolution.

    [0055] The term “gene” is used broadly to refer to any nucleic acid associated with a biological function. The term “gene” applies to a specific genomic sequence, as well as to a cDNA or an mRNA encoded by that genomic sequence.

    [0056] “Identity” as between nucleic acid sequences of two nucleic acid molecules can be determined as a percentage of identity using known computer algorithms such as the “FASTA” program, using for example, the default parameters as in Pearson et al. (1988) Proc. Natl. Acad. Sci. USA 85:2444 (other programs include the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(I):387 (1984)), BLASTP, BLASTN, FASTA Atschul, S. F., et al., J Molec Biol 215:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo et al. (1988) SIAM J Applied Math 48:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include, DNAStar “MegAlign” program (Madison, Wis.) and the University of Wisconsin Genetics Computer Group (UWG) “Gap” program (Madison Wis.)).

    [0057] The term “increase” means a change, such that the difference is, depending on circumstances, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 4-fold, 10-fold, 100-fold, 10{circumflex over ( )}9 fold, 10{circumflex over ( )}4 fold, 10{circumflex over ( )}5 fold, 10{circumflex over ( )}6 fold, and/or 10{circumflex over ( )}7 fold greater after treatment when compared to a pre-treatment state. Properties that may be increased include immune cells, bacterial cells, stromal cells, myeloid derived suppressor cells, fibroblasts, metabolites, and cytokines.

    [0058] “Operational taxonomic units” and “OTU(s)” refer to a terminal leaf in a phylogenetic tree and is defined by a nucleic acid sequence, e.g., the entire genome, or a specific genetic sequence, and all sequences that share sequence identity to this nucleic acid sequence at the level of species. In some embodiments the specific genetic sequence may be the 16S sequence or a portion of the 16S sequence. In other embodiments, the entire genomes of two entities are sequenced and compared. In another embodiment, select regions such as multilocus sequence tags (MLST), specific genes, or sets of genes may be genetically compared. For 16S, OTUs that share ≥97% average nucleotide identity across the entire 16S or some variable region of the 16S are considered the same OTU. See e.g. Claesson M J, Wang Q, O'Sullivan O, Greene-Diniz R, Cole J R, Ross R P, and O'Toole P W. 2010. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res 38: e200. Konstantinidis K T, Ramette A, and Tiedje J M. 2006. The bacterial species definition in the genomic era. Philos Trans R Soc Lond B Biol Sci 361: 1929-1940. For complete genomes, MLSTs, specific genes, other than 16S, or sets of genes OTUs that share ≥95% average nucleotide identity are considered the same OTU. See e.g., Achtman M, and Wagner M. 2008. Microbial diversity and the genetic nature of microbial species. Nat. Rev. Microbiol. 6: 431-440. Konstantinidis K T, Ramette A, and Tiedje J M. 2006. The bacterial species definition in the genomic era. Philos Trans R Soc Lond B Biol Sci 361: 1929-1940. OTUs are frequently defined by comparing sequences between organisms. Generally, sequences with less than 95% sequence identity are not considered to form part of the same OTU. OTUs may also be characterized by any combination of nucleotide markers or genes, in particular highly conserved genes (e.g., “house-keeping” genes), or a combination thereof. Operational Taxonomic Units (OTUs) with taxonomic assignments made to, e.g., genus, species, and phylogenetic Glade are provided herein.

    [0059] “Strain” refers to a member of a bacterial species with a genetic signature such that it may be differentiated from closely-related members of the same bacterial species. The genetic signature may be the absence of all or part of at least one gene, the absence of all or part of at least on regulatory region (e.g., a promoter, a terminator, a riboswitch, a ribosome binding site), the absence (“curing”) of at least one native plasmid, the presence of at least one recombinant gene, the presence of at least one mutated gene, the presence of at least one foreign gene (a gene derived from another species), the presence at least one mutated regulatory region (e.g., a promoter, a terminator, a riboswitch, a ribosome binding site), the presence of at least one non-native plasmid, the presence of at least one antibiotic resistance cassette, or a combination thereof. Genetic signatures between different strains may be identified by PCR amplification optionally followed by DNA sequencing of the genomic region(s) of interest or of the whole genome. In the case in which one strain (compared with another of the same species) has gained or lost antibiotic resistance or gained or lost a biosynthetic capability (such as an auxotrophic strain), strains may be differentiated by selection or counter-selection using an antibiotic or nutrient/metabolite, respectively.

    Manufacturing Process

    [0060] In certain aspects, provided herein are methods of culturing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor under an anaerobic atmosphere comprising CO.sub.2, e.g., greater than 1% CO.sub.2 (e.g., greater than 5% CO.sub.2). In certain aspects, provided herein are methods of growing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor into which a gas mixture comprising CO.sub.2 is introduced e.g., greater than 1% CO.sub.2 (e.g., greater than 5% CO.sub.2). In some embodiments, provided herein are methods culturing anaerobic bacteria, the method comprising the steps of a) purging a bioreactor with an anaerobic gas mixture comprising greater than 1% CO.sub.2; and b) culturing the anaerobic bacteria in the bioreactor purged in step a) (e.g., while a gas mixture comprising greater than 1% CO.sub.2 is introduced into the bioreactor).

    [0061] In certain aspects, provided herein are methods of culturing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor under an anaerobic atmosphere comprising N.sub.2, e.g., less than 95% N.sub.2 (e.g., less than 90% N.sub.2). In certain aspects, provided herein are methods of culturing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor into which a gas mixture comprising N.sub.2 is introduced, e.g., less than 95% N.sub.2 (e.g., less than 90% N.sub.2). In some embodiments, provided herein are methods culturing anaerobic bacteria, the method comprising the steps of a) purging a bioreactor with an anaerobic gas mixture comprising less than 95% N.sub.2; and b) culturing the anaerobic bacteria in the bioreactor purged in step a) (e.g., while a gas mixture comprising less than 95% N.sub.2 is introduced into the bioreactor).

    [0062] Schematic representations providing exemplary manufacturing methods according to certain embodiments provided herein are depicted in FIGS. 1 and 2.

    [0063] In certain embodiments, culturing anaerobic bacteria according to a method provided herein results in an improved yield of anaerobic bacteria. In certain embodiments, the yield is improved by a factor of at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2.0-fold, 2.1-fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold or 3.0-fold. In some embodiments, the yield is improved by a factor of between 1.5-fold and 4.0-fold. In some embodiments, the yield is improved by a factor of between 2-fold and 3-fold.

    [0064] In some embodiments, the methods provided herein reduce contamination of the anaerobic bacteria culture. For example, the methods provided herein can prevent the outgrowth or overgrowth of a contaminant in the anaerobic bacteria culture. Contaminants can include, e.g., bacterial strains present in air flow or gas flow and/or environmental strains, e.g., present at a manufacturing facility.

    [0065] In certain aspects, provided herein are methods of growing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor under an anaerobic atmosphere comprising CO.sub.2. In some embodiments, the anaerobic atmosphere comprises greater than 1% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises at least about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, CO.sub.2. In some embodiments, the anaerobic atmosphere comprises greater than 5% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises at least 8% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises at least 10% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises at least 20% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises from 8% to 40% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises from 10% to 40% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises from 20% to 30% CO.sub.2. In some embodiments, the anaerobic atmosphere comprises about 25% CO.sub.2.

    [0066] In certain aspects, provided herein are methods of growing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor into which an anaerobic gas mixture comprising CO.sub.2 is introduced. In some embodiments, the anaerobic gas mixture comprises greater than 1% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, CO.sub.2. In some embodiments, the anaerobic gas mixture comprises greater than 5% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 8% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 10% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 20% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 8% to 40% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 10% to 40% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 20% to 30% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises about 25% CO.sub.2.

    [0067] In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 95% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 95%, less than 92%, less than 90%, less than 87%, less than 85%, less than 82%, less than 80%, less than 77% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 85% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 80% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 65% to 85% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 70% to 80% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 75% N.sub.2.

    [0068] In some embodiments, the anaerobic atmosphere and/or gas mixture consists essentially of CO.sub.2 and N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 25% CO.sub.2 and about 75% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 20% CO.sub.2 and about 80% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 30% CO.sub.2 and about 70% N.sub.2.

    [0069] In certain aspects, provided herein are methods of culturing anaerobic bacteria, the method comprises the steps of a) purging a bioreactor with an anaerobic gas mixture comprising greater than 1% CO.sub.2; and b) culturing the anaerobic bacteria in the bioreactor purged in step a). In some embodiments the method comprises introducing the anaerobic gas mixture into the bioreactor during step b). In some embodiments, the anaerobic gas mixture comprises greater than 1% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%, CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 5% to 35% CO.sub.2, 10% to 40% CO.sub.2, 10% to 30% CO.sub.2, 15% to 30% CO.sub.2, 20% to 30% CO.sub.2, 22% to 28% CO.sub.2, or 24%, to 26% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises greater than 5% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 8% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 10% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises at least 20% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 8% to 40% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 10% to 40% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises from 20% to 30% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises about 25% CO.sub.2. In some embodiments, CO.sub.2 gas is continuously added during culturing.

    [0070] In certain aspects, provided herein are methods of culturing anaerobic bacteria, the method comprises the steps of a) purging a bioreactor with an anaerobic gas mixture comprising less than 95% N.sub.2; and b) culturing the anaerobic bacteria in the bioreactor purged in step a). In some embodiments the method comprises introducing the anaerobic gas mixture into the bioreactor during step b). In some embodiments, the anaerobic gas mixture comprises less than 95% N.sub.2. In some embodiments, the anaerobic gas mixture comprises less than 95%, less than 92%, less than 90%, less than 87%, less than 85%, less than 82%, less than 80%, less than 77% N.sub.2. In some embodiments, the anaerobic gas mixture comprises about 65%, about 66%, about 67%, about 28%, about 69%, about 70%, about 71%, about 72% about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85% N.sub.2. In some embodiments, the anaerobic gas mixture comprises less than 95% N.sub.2. In some embodiments, the anaerobic gas mixture comprises less than 90% N.sub.2. In some embodiments, the anaerobic gas mixture comprises from 65% to 85% N.sub.2. In some embodiments, the anaerobic gas mixture comprises from 70% to 80% N.sub.2CO.sub.2. In some embodiments, the anaerobic gas mixture comprises about 75% N.sub.2.

    [0071] In some embodiments, the anaerobic gas mixture consists essentially of CO.sub.2 and N.sub.2. In some embodiments, the anaerobic gas mixture comprises about 25% CO.sub.2 and about 75% N.sub.2. In some embodiments, the anaerobic atmosphere comprises about 20% CO.sub.2 and about 80% N.sub.2. In some embodiments, the anaerobic atmosphere comprises about 30% CO.sub.2 and about 70% N.sub.2.

    [0072] In some embodiments, the anaerobic gas mixture comprises CO.sub.2 and N.sub.2 in a ratio of about 1:99, about 2:98, about 3:97, about 4:96, about 5:95, about 6:94, about 7:93, about 8:92, about 9:91, about 10:90, 11:89, about 12:88, about 13:87, about 14:86, about 15:85, about 16:84, about 17:83, about 18:82, about 19:81, about 20:80, 21:79, about 22:78, about 23:77, about 24:76, about 25:75, about 26:74, about 27:73, about 28:72, about 29:71, about 30:70, 31:69, about 32:68, about 33:67, about 34:66, about 35:65, about 36:64, about 37:63, about 38:62, about 39:61, or about 40:50 CO.sub.2 to N.sub.2.

    [0073] In some embodiments, an anaerobic gas mixture is continuously added to the bioreactor during culturing. In some embodiments, the continuously added anaerobic gas mixture is added at a rate of 0.001 to 0.1 vvm. In some embodiments the continuously added anaerobic gas mixture is added at a rate of about 0.001, about 0.002, about 0.003, about 0.004, about 0.005, about 0.006, about 0.007, about 0.008, about 0.009, about 0.01, about 0.011, about 0.012, about 0.013, about 0.014, about 0.015, about 0.016, about 0.017, about 0.018, about 0.019, about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, or about 0.1 vvm. In some embodiments the continuously added anaerobic gas mixture is added at a rate of 0.02 vvm. In some embodiments the continuously added anaerobic gas mixture is added at a rate of about 0.002 vvm. In some embodiments, CO.sub.2 gas is continuously added to the bioreactor during culturing. In some embodiments, the continuously added CO.sub.2 gas is added at a rate of 0.001 to 0.1 vvm. In some embodiments the continuously added CO.sub.2 gas is added at a rate of about 0.001, about 0.002, about 0.003, about 0.004, about 0.005, about 0.006, about 0.007, about 0.008, about 0.009, about 0.01, about 0.011, about 0.012, about 0.013, about 0.014, about 0.015, about 0.016, about 0.017, about 0.018, about 0.019, about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, or about 0.1 vvm. In some embodiments the continuously added a CO.sub.2 gas is added at a rate of about 0.02 vvm. In some embodiments the continuously added CO.sub.2 is added at a rate of about 0.007 vvm. In some embodiments, CO.sub.2 is added at a rate of about 0.1 vvm.

    [0074] In certain aspects, provided herein are bioreactors comprising anaerobic bacteria under an anaerobic atmosphere comprising at least about 1% CO.sub.2 and/or into which an anaerobic gas mixture comprising at least about 1% CO.sub.2 is added. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises greater than 5% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises at least 8% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises at least 20% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 8% to 40% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 10% to 40% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 20% to 30% CO.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 25% CO.sub.2.

    [0075] In certain aspects, provided herein are bioreactors comprising anaerobic bacteria under an anaerobic atmosphere comprising less than 95% N.sub.2 and/or into which an anaerobic gas mixture comprising less than 95% N.sub.2 is added. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 90% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises less than 85% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 65% to 85% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises from 70% to 80% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 75% N.sub.2.

    [0076] In some embodiments, the anaerobic atmosphere and/or gas mixture consists essentially of CO.sub.2 and N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 25% CO.sub.2 and about 75% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 20% CO.sub.2 and about 80% N.sub.2. In some embodiments, the anaerobic atmosphere and/or gas mixture comprises about 30% CO.sub.2 and about 70% N.sub.2. In some embodiments, the bioreactor is at least 1 L, 20 L, 3500 L, 20,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L, 400,000 L or 500,000 L.

    [0077] In certain aspects, provided herein are methods of growing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor comprising carbonate salt. In some embodiments, is sodium carbonate, potassium carbonate, barium carbonate, carbonic acid, magnesite (magnesium carbonate), sodium percarbonate (adduct with hydrogen peroxide), or calcium carbonate. In some embodiments, the carbonate is at a concentration of 0.5 g/L to 10 g/L. In some embodiments, the carbonate salt is at a concentration of 0.5 to 1 g/L, 1 to 5 g/L, or 2 to 8 g/L. In some embodiments, the carbonate salt is at a concentration of about 0.5 g/L, about 1 g/L, about 5 g/L, or about 10 g/L. In some embodiments, the bioreactor is at least 1 L, 20 L, 3500 L, 20,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L, 400,000 L or 500,000 L.

    [0078] In certain aspects, provided herein are methods of growing anaerobic bacteria comprising culturing the anaerobic bacteria in a bioreactor comprising bicarbonate salt. In some embodiments, the bicarbonate salt is sodium bicarbonate, potassium bicarbonate, cesium bicarbonate, magnesium bicarbonate, or ammonium bicarbonate. In some embodiments, the bicarbonate salt is at a concentration of 0.5 g/L to 10 g/L. In some embodiments, the bicarbonate salt is at a concentration of 0.5 to 1 g/L, 1 to 5 g/L, or 2 to 8 g/L. In some embodiments, the bicarbonate salt is at a concentration of about 0.5 g/L, about 1 g/L, about 5 g/L, or about 10 g/L. In some embodiments, the bioreactor is at least 1 L, 20 L, 3500 L, 20,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L, 400,000 L or 500,000 L.

    [0079] In some embodiments, the methods and compositions provided herein include the culturing of anaerobic bacteria in growth media. In some embodiments the growth media may contain sugar, yeast extracts, plant based peptones, buffers, salts, trace elements, surfactants, anti-foaming agents, and/or vitamins.

    [0080] The sugar source present in the growth media can affect growth. For example, use of maltodextrin (e.g., glucidex, e.g., glucidex 21D) can provide better growth than use of glucose, e.g., at the same concentration of each sugar source, e.g., about 10 g/L. Alternatively, maltodextrin and glucose can both be used in the growth media, e.g., glucose at 10 g/L and maltodextrin at 25 g/L. For example, use of maltodextrin (e.g., glucidex, e.g., glucidex 21D) and glucose can provide better growth than use of glucose alone, e.g., at the same total concentration, e.g., about 35 g/L total sugar. In some embodiments, the growth media comprises glucose. In some embodiments, the growth media comprises maltodextrin. In some embodiments, the growth media comprises glucose and maltodextrin.

    [0081] In some embodiments, the growth media comprises yeast extract, soy peptone A2SC 19649, Soy peptone E110 19885, dipotassium phosphate, monopotassium phosphate, L-cysteine-HCl, ammonium chloride, maltodextrin (e.g., glucidex, e.g., glucidex 21D), glucose, and/or hemoglobin. In some embodiments, the growth media comprises 5 g/L to 15 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L to 15 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 12.5 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 10 g/L to 15 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 12.5 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 1 g/L to 2 g/L dipotassium phosphate. In some embodiments, the growth media comprises 1.59 g/L Dipotassium phosphate. In some embodiments, the growth media comprises 0.5 g/L to 1.5 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.91 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.5 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L ammonium chloride. In some embodiments, the growth media comprises 0.5 g/L ammonium chloride. In some embodiments, the growth media comprises 20 g/L to 30 g/L maltodextrin (e.g., glucidex, e.g., glucidex 21D). In some embodiments, the growth media comprises 25 g/L maltodextrin (e.g., glucidex, e.g., glucidex 21D). In some embodiments, the growth media comprises 5 g/L to 15 g/L glucose. In some embodiments, the growth media comprises 10 g/L glucose. In some embodiments, the growth media comprises 0.01 g/L to 0.05 g/L hemoglobin. In some embodiments, the growth media comprises 0.02 g/L hemoglobin.

    [0082] In some embodiments, the growth media comprises yeast extract, soy peptone A2SC 19649, Soy peptone E110 19885, dipotassium phosphate, monopotassium phosphate, L-cysteine-HCl, ammonium chloride, glucose, and/or hemoglobin. In some embodiments, the growth media comprises 5 g/L to 15 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L to 15 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 12.5 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 10 g/L to 15 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 12.5 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 1 g/L to 2 g/L dipotassium phosphate. In some embodiments, the growth media comprises 1.59 g/L Dipotassium phosphate. In some embodiments, the growth media comprises 0.5 g/L to 1.5 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.91 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.5 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L ammonium chloride. In some embodiments, the growth media comprises 0.5 g/L ammonium chloride. In some embodiments, the growth media comprises 5 g/L to 15 g/L glucose. In some embodiments, the growth media comprises 10 g/L glucose. In some embodiments, the growth media comprises 0.01 g/L to 0.05 g/L hemoglobin. In some embodiments, the growth media comprises 0.02 g/L hemoglobin.

    [0083] In some embodiments, the growth media comprises yeast extract, soy peptone A2SC 19649, Soy peptone E110 19885, dipotassium phosphate, monopotassium phosphate, L-cysteine-HCl, ammonium chloride, maltodextrin (e.g., glucidex, e.g., glucidex 21D), and/or hemoglobin. In some embodiments, the growth media comprises 5 g/L to 15 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L yeast extract 19512. In some embodiments, the growth media comprises 10 g/L to 15 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 12.5 g/L soy peptone A2SC 19649. In some embodiments, the growth media comprises 10 g/L to 15 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 12.5 g/L Soy peptone E110 19885. In some embodiments, the growth media comprises 1 g/L to 2 g/L dipotassium phosphate. In some embodiments, the growth media comprises 1.59 g/L Dipotassium phosphate. In some embodiments, the growth media comprises 0.5 g/L to 1.5 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.91 g/L monopotassium phosphate. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.5 g/L L-cysteine-HCl. In some embodiments, the growth media comprises 0.1 g/L to 1.0 g/L ammonium chloride. In some embodiments, the growth media comprises 0.5 g/L ammonium chloride. In some embodiments, the growth media comprises 20 g/L to 30 g/L maltodextrin (e.g., glucidex, e.g., glucidex 21D). In some embodiments, the growth media comprises 25 g/L maltodextrin (e.g., glucidex, e.g., glucidex 21D). In some embodiments, the growth media comprises 0.01 g/L to 0.05 g/L hemoglobin. In some embodiments, the growth media comprises 0.02 g/L hemoglobin.

    [0084] In some embodiments, the media is sterilized. Sterilization may be by Ultra High Temperature (UHT) processing, autoclaving or filtering. The UHT processing is performed at very high temperature for short periods of time. The UHT range may be from 135-180° C. For example, the medium may be sterilized from between 10 to 30 seconds at 135° C.

    [0085] In some embodiments, inoculum can be prepared in flasks or in smaller bioreactors where growth is monitored. For example, the inoculum size may be between approximately 0.1% v/v and 5% v/v of the total bioreactor volume. In some embodiments, the inoculum is 0.1-3% v/v, 0.1-1% v/v, 0.1-0.5% v/v, or 0.5-1% v/v of the total bioreactor volume. In some embodiments, the inoculum is 0.1% v/v, 0.2% v/v, 0.3% v/v, 0.4%, v/v, 0.5% v/v, 0.6% v/v, 0.7% v/v, 0.8% v/v, 0.9% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v 4%, v/v, or 5% v/v of the total bioreactor volume.

    [0086] Depending on the application and need for material, bioreactor volume can be at least 1 L, 2 L, 10 L, 80 L, 100 L, 250 L, 1000 L, 2500 L, 3500 L, 5000 L, 10,000 L, 20,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L, 400,000 L or 500,000 L.

    [0087] In some embodiments, before the inoculation, the bioreactor is prepared with growth medium at desired pH and temperature. The initial pH of the culture medium may be different that the process set-point. pH stress may be detrimental at low cell centration; the initial pH could be between pH 7.5 and the process set-point. For example, pH may be set between 4.5 and 8.0, preferably 6.5. During the fermentation, the pH can be controlled through the use of sodium hydroxide, potassium hydroxide, or ammonium hydroxide. The temperature may be controlled from 25° C. to 45° C., for example at 37° C.

    [0088] In certain embodiments, anaerobic conditions are created by reducing the level of oxygen in the bioreactor by introducing or purging the bioreactor with nitrogen, carbon dioxide or gas mixtures (N.sub.2 and CO.sub.2) in order to establish an anaerobic atmosphere in the bioreactor.

    [0089] In some embodiments, the atmosphere comprises at least about 2% to about 40% CO.sub.2, about 5% to 35% CO.sub.2, about 10% to 30% CO.sub.2, about 15% to 30% CO.sub.2, about 20% to 30% CO.sub.2, about 22% to 28% CO.sub.2, or about 24% to 26% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises greater than 5% CO.sub.2. In some preferred embodiments, the atmosphere comprises about 25% CO.sub.2.

    [0090] In some embodiments, the atmosphere comprises at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% CO.sub.2. In some embodiments, the anaerobic gas mixture comprises greater than 5% CO.sub.2. In some preferred embodiments, the atmosphere comprises at least about 25% CO.sub.2.

    [0091] In some embodiments, the atmosphere comprises 65% to 85% N.sub.2 or 70% to 80% N.sub.2. In some embodiments, the anaerobic gas mixture comprises less than 95% N.sub.2. In some preferred embodiments, the atmosphere comprises about 75% N.sub.2.

    [0092] In some embodiments, the atmosphere comprises about 65%, about 66%, about 67%, about 28%, about 69%, about 70%, about 71%, about 72% about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85% N.sub.2. In some embodiments, the anaerobic gas mixture comprises less than 95% N.sub.2. In some preferred embodiments, the atmosphere comprises about 75% N.sub.2.

    [0093] In some embodiments, the gas mixture (CO.sub.2 and N.sub.2) provides an atmosphere in the bioreactor comprising CO.sub.2 and N.sub.2 in a ratio of about 1:99, about 2:98, about 3:97, about 4:96, about 5:95, about 6:94, about 7:93, about 8:92, about 9:91, about 10:90, 11:89, about 12:88, about 13:87, about 14:86, about 15:85, about 16:84, about 17:83, about 18:82, about 19:81, about 20:80, 21:79, about 22:78, about 23:77, about 24:76, about 25:75, about 26:74, about 27:73, about 28:72, about 29:71, about 30:70, 31:69, about 32:68, about 33:67, about 34:66, about 35:65, about 36:64, about 37:63, about 38:62, about 39:61, or about 40:50 CO.sub.2 to N.sub.2. In some embodiments, the mixed gas composition provides an atmosphere in the bioreactor comprising CO.sub.2 and N.sub.2 in a ratio of about 25:75.

    [0094] In some embodiments, depending on strain and inoculum size, the bioreactor fermentation time can vary. For example, fermentation time can vary from approximately 5 hours to 48 hours. In some embodiments, fermentation time may be from about 5 hours to about 24 hours, about 8 hours to about 24 hours, about 8 hours to about 18 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 10 hours to about 24 hours, about 10 hours to about 18 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 24 hours, about 12 hours to about 18 hours, about 12 hours to about 16 hours, or about 12 hours to about 14 hours. In some embodiments, fermentation time may be from about 12 hours to about 96 hours, from about 12 hours to about 72 hours, from about 12 hours to about 60 hours, from about 24 hours to about 96 hours, from about 24 hours to about 72 hours, from about 24 hours to about 60 hours, from about 24 hours to about 48 hours, from about 36 hours to about 96 hours, from about 36 hours to about 72 hours, from about 36 hours to about 60 hours, or from about 36 hours to about 48 hours.

    [0095] In some embodiments, fermentation culture is continuously mixed with addition of a mixed gas composition of CO.sub.2 and N.sub.2. In some embodiments, the mixed gas composition provides an atmosphere in the bioreactor comprising CO.sub.2 and N.sub.2 in a ratio of about 1:99, about 2:98, about 3:97, about 4:96, about 5:95, about 6:94, about 7:93, about 8:92, about 9:91, about 10:90, 11:89, about 12:88, about 13:87, about 14:86, about 15:85, about 16:84, about 17:83, about 18:82, about 19:81, about 20:80, 21:79, about 22:78, about 23:77, about 24:76, about 25:75, about 26:74, about 27:73, about 28:72, about 29:71, about 30:70, 31:69, about 32:68, about 33:67, about 34:66, about 35:65, about 36:64, about 37:63, about 38:62, about 39:61, or about 40:50 CO.sub.2 to N.sub.2. In some embodiments, the mixed gas composition provides an atmosphere in the bioreactor comprising CO.sub.2 and N.sub.2 in a ratio of about 25:75.

    [0096] In certain embodiments, harvest time may be based on either glucose level is below 2 g/L or when stationary phase is reached.

    [0097] In some embodiments, once fermentation complete, the culture is cooled (e.g., to 10° C.) and centrifuged collecting the cell paste. A stabilizer may be added to the cell paste and mixed thoroughly. Harvesting may be performed by continuous centrifugation. Product may be resuspended with various excipients to a desired final concentration. Excipients can be added for cryo protection or for protection during lyophilization. Excipients can include, but are not limited to, sucrose, trehalose, or lactose, and these may be alternatively mixed with buffer and anti-oxidants. Prior to lyophilization, droplets of cell pellets may be mixed with excipients and submerged in liquid nitrogen.

    [0098] In certain embodiments, the cell slurry may be lyophilized. Lyophilization of material, including live bacteria, may begin with primary drying. During the primary drying phase, the ice is removed. Here, a vacuum is generated and an appropriate amount of heat is supplied to the material for the ice to sublime. During the secondary drying phase, product bound water molecules may be removed. Here, the temperature is raised higher than in the primary drying phase to break any physico-chemical interactions that have formed between the water molecules and the product material. The pressure may also be lowered further to enhance desorption during this stage. After the freeze-drying process is complete, the chamber may be filled with an inert gas, such as nitrogen. The product may be sealed within the freeze dryer under dry conditions, preventing exposure to atmospheric water and contaminants. The lyophilized material may be gamma irradiated (e.g., 17.5 kGy).

    Anaerobic Bacteria

    [0099] In some aspects, provided herein are methods and compositions for culturing anaerobic bacteria. In certain aspects, the anaerobic bacteria used in the methods and compositions provided herein are selected from bacteria of the genus Actinomyces, Bacteroides, Clostridium, Fusobacterium, Peptostreptococcus, Porphyromonas, Prevotella, Propionibacterium, or Veillonella.

    [0100] In some embodiments, the anaerobic bacteria are Prevotella bacteria of the species Prevotella albensis, Prevotella amnii, Prevotella bergensis, Prevotella bivia, Prevotella brevis, Prevotella bryantii, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella histicola, Prevotella melanogenica, Prevotella intermedia, Prevotella maculosa, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nigrescens, Prevotella oralis, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella salivae, Prevotella stercorea, Prevotella tannerae, Prevotella timonensis, Prevotella jejuni, Prevotella aurantiaca, Prevotella baroniae, Prevotella colorans, Prevotella corporis, Prevotella dentasini, Prevotella enoeca, Prevotella falsenii, Prevotella fusca, Prevotella heparinolytica, Prevotella loescheii, Prevotella multisaccharivorax, Prevotella nanceiensis, Prevotella oryzae, Prevotella paludivivens, Prevotella pleuritidis, Prevotella ruminicola, Prevotella saccharolytica, Prevotella scopos, Prevotella shahii, Prevotella zoogleoformans, or Prevotella veroralis.

    [0101] In some embodiments, the Prevotella is Prevotella Strain B 50329 (NRRL accession number B 50329). In some embodiments, the Prevotella strain is a strain comprising at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity (e.g., at least 99.5% sequence identity, at least 99.6% sequence identity, at least 99.7% sequence identity, at least 99.8% sequence identity, at least 99.9% sequence identity) to the nucleotide sequence (e.g., genomic sequence, 16S sequence, CRISPR sequence) of the Prevotella Strain B 50329.

    [0102] In some embodiments, the Prevotella bacteria is a strain of Prevotella bacteria comprising one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more) proteins listed in Table 1 and/or one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more) genes encoding proteins listed in Table 1. In some embodiments, the Prevotella bacteria comprises all of the proteins listed in Table 1 and/or all of the genes encoding the proteins listed in Table 1.

    TABLE-US-00001 TABLE 1 Exemplary Prevotella proteins Seq. ID. No. Name Uniprot ID Amino Acid Sequence  1 Cluster: G6ADE1 MNLKTFTKTVLCFALFAVSAITAKAADHLAIVGE Uncharacterized AVWGGWDLVKATAMVKSPNNPDVFMATVHLNAGK protein GFKFLTEREWGKLEYRSGASDVVLKSGIRYKLYA SIGASEDGKFKVSESANYEIICDLARKTVEVKKV AYQAKEIRYAALWMIGDATAGDWDYNNGVLLSQD SGNPTCYTATVELKEGEFKFTTNKQWGYDHSVYI FRDVNDQNKIVFGGEDNKWRITEDGMYNVTVDVP TKTISIKQIDDPAGHKPQFGNDVILVGDATIAGW NLDNAIYLEHTGQAGRVFKTTTYLEAGKGFKFLS MLSYDDIDYRPANNTVLNPGVPGTFVPSLPSSTD TKFSVERSGNYDIVCNMNNRTVVVTLSENQVLVN YPALWLIGSATSAGWNPGKAVELKRSEADPAVYT ARVQLKKGEFKILTSKNVGFDQPTYYRDSTNEHR IVFGVDGDEVAKKDCKWTLSENAEGTYDVTVDIE AMTIFCDKVNMDEPSVESTDKELILIGDATYSAW DLPKSIVMTPVGPTTFKAVTHLEAGKEFKFLTEL AWKRYEYRAESLRKELQEGSMSMLVPYRYTNDKD DKDHDFKFVVKESGNYEIVCDLYIPALIIRKVRY QDTPVTYSSLWIVGSATPGGWTIERGIKMTQDEN YPTKFTAKANLVPGELKFATNKFADFTQDFFFRG KDDYTAVLGGNDNKWNITEAGTYSVTIDVASKRV TITKPARNAPTGISTVDSSDEAPAEYFTLNGIKV TTPSSGIYIKRQGGRTTKVVMK  2 Nicotinamide_ P24520 MDTYQILDIIGCIVGLIYIYQEYKASIWLWMTGI riboside_ IMPVIYMFVYYEAGLYADFGMQIYYTLAAIYGYL transporter_PnuC YWKLGKKKGTEDKEIPITHFPRRYIIPAIIVFFV LWIALYYILICFTNSTVPVLDSFGNALSFIGLWA LAKKYLEQWWIWIVVDAELSALYIYKGIPFTAML YALYTVIAVAGYFKWRRYIKQQK  3 Pectate_trisaccharide- Q8GCB2 MRVRLYKNILLFLFLWVNTLACVSADTSRTVESQ lyase PIENGLIITESKGWLETIYAKWKPVAEADGYYVY VKGGQYADYSKVDSELIRVYNGYVRVDIPGLKAG TYSLKIVAVKGGKETQSSEVTGLKVLNYVREGFA HKNYSGVGAYNDDGTLKSGAVVIYVNKDNAKTVS AHLGKTTFIGLQAILNAYQKGNITTPLSVRILGL LRNGDTDTFGSSTEGIQIKGKQADSEMNITIEGI GEDASIYGFGFLVRNAKSVEFRNLGIMRAMDDGV SLDTNNSNIWIHHMDLFYGKASGGDHIKGDGSID VKTDSKYVTIDNCHFWDTGKTSMCGMKKETGPNY ITYHHNWFDHSDSRHARVRTMSVHLWNNYYDGCA KYGIGATMGCSVFSENNYFRATKNPILISKQGSD AKGTGKFSGEPGGMVKEYGSLFTEKGAESTYTPI SYADNNSSFDFYHAISRNEKVPASVKTLNGGNIY NNFDTDAALMYSYTPDATALVPSQVTGFYGAGRL NHGSLQFKFNNAVEDTNSTPIPALEALIDAYSGK  4 Glycosyltransferase_ Q9AET5 MKYNIAYCIEGFYNHGGMERILSVCANLLSDIYS Gtf1 ITIIVANQRGREHAYNLAQNVNVVDLGVSCKNYK EEYKKSLTRYLQDHQFSVVISLAGLELFFLPQIK DGSKKVMWFHFAFDVSKMFLSERFHGWKLNLLYY IHTIRRIYFAKKFDTIVVLSKSDCDSWSRFCNNV KYIYNPITIDRKVISNLSEESVIAVGRLGWQKGF DFLIDSWVLVDDKHPDWHLDIFGEGPDRLELQHQ IDRKGLHDKVRLCGVTKQIEEEYGKHSIYVMSSR AEGFPLALLEASSCGLPMISFNCHQGPNEIIQEG ENGFLVDKVGDIYTLSDRICKLIEDNNLRNMMGK KALDSSFRFEGEVIKKDWISLLKQLI  5 Cluster: Protein A0A096B759 MKRLFFMFLFLGTITMNSLAQEEKPIKYETKNFS TonB LPDKMPLYPGGDGALRAFLSLNLHYPEKAQAFGV EGRSLMKFCVSSDGSIKDISAVDCKITNYNRTEF NKLPLSKQESLKKECAKAFAKEAARVIRLMPKWE PAELNGKKMNVYYSLPFTFKLR  6 Cluster: G6AEN6 MNYPLFIARKIYNGGDRTRKVSKPAIRIATIGVA Uncharacterized IGLAVMIISVGVVLGFKHTIRNKVVGFGSDITVA protein NFLTLQSSEQYPIQITDSLVKSLQITPGIKHVQR YDYTQGILKTDNDFLGVLLKGVGPDFDSTFIHEN MVEGSLPHFHDNESQQKIVISKTIADKLNLKVGQ RIFAYFINKQGVRTRKFTITGIYATNMKQFDSQI CFTDIYTTNKLNGWEPDQYSGAELQVDNFSQLTP ISMRVLNKVKNTVDHYGGTYSSENIIEQNPQIFS WLDLMDMNVWIILALMISVAGVTMISGLLIIILE RTQMIGILKALGSRNRQIRHIFLWFATFIIGKGL LWGNIIGLGCILFQSWTGLVKLDPQTYYVNTVPV EINIPLIIALNMVTMLVCLVILIAPSYLISHIHP AKSMHYE  7 Bifunctional_ P9WHG9 MEDKFIYTDKERKLSYQILDELKDTLDKSFLEND (p)ppGpp_synthase/ LPMLQVQLKDSVAKNTIHRNVFGLNPILCSLQTA hydrolase_RelA AIAVKDIGLKRDSVIAILLHQSVQDGYITLEDID NRFGKSVAKIIHGLIRIQTLYQKNPIIESENFRN LLLSFAEDMRVILIMIADRVNLMRQIRDAEDKEA QHKVAEEASYLYAPLAHKLGLYQLKRELEDLSLK YLEHDAYYLIKDKLNATKASRDAYINQFIAPVRE RLTAGGLRFHIKGRTKSIHSIWQKMKKQKCGFEG IYDLFAIRIILDAPLEKEKIQCWQAYSIVTDMYQ PNPKRLRDWLSVPKSNGYECLHITVLGPEKKWVE VQIRTERMDEIAEHGLAAHWRYKGIKEEGGLDDW LASIRAALEAGDNLEVMDQFKSDLYEKEIYVFTP KGDLLKFPKGATILDFAYHIHSKVGNQCVGGKIN AKNVSLRTELHSGDTVEILTSATQKPKAEWLKIV KSSRAKAKIRLALKETQIKDGLYAKELLERRFKN KKIEIEESTMGHLLRKLGFKEVSEFYKQVADEKL DPNYIIEEYQKVYNHDHNLNQPKETESAENFEFE NPTNEFLKKNDDVLVIDKNLKGLDFSLAKCCHPI YGDPVFGFVTVNGGIKIHRTDCPNAPEMRKRFGY RIVKARWSGKGSSQYAITLRVIGNDDIGIVSNIT NVISKDEKIVMRSINIDSHDGLFSGNLVVLLDDN SKLNMLIKKLRTVKGVKQVTRI  8 Vitamin_B12_ P06609 MKRRIFLFVALSVSIVILFGLNLIIGSVHIPLSD import_system_ ILTILSGSFTGKESWRFIIWDSRLPQALTAMLCG permease_protein_BtuC SSLAVCGLMLQTAFRNPLAGPDVFGISSGASLGV ALVMLLLGGTVETSMFTASGFLAILIVAFAGAIL VTAFILFLSSVVRNSVLLLIVGIMVGYVASSAVT LLNFFSSEDGVKGYIVWGMGNFGGVSMSHIPLFA FLCLAGIIASFLLVKPLNILLLGPQYAESLGISI RRIRNILLVVVGILTAVTTAFCGPISFIGLAAPH VARLLFRTENHQKLLPGTLLVGTVVALLCNLICF LPRESGMIPLNAVTPLIGAPIIIYVIMKRH  9 NADH- P33599 MKLENKEFGFDSFATEMARLKNEKHFDYLVTVVG quinone_ EDFGTEEGLGCIYILENTSTHERCSVKQLAKKVG oxidoreductase_ EEFVIPSVIKLWADADLLEREVYDFYGIKFLGHP subunit_C/D DMRRLFLRNDFKGYPLRKDYDMDPAKNMYTTEDD VELDTTTEWNLDKNGELVGTQHALFTDDNFVVNI GPQHPSTHGVLRLQTVLDGETVTNIYPHLGYIHR GIEKLCEQFTYPQTLALTDRMNYLSAMMNRHALV GVIEEGMGIELSERILYIRTIMDELQRIDNHLLY TACCAQDLGALTAFLYGMRDREHVLNVMEETTGG RLIQNYYRIGGLQADIDPNFVSNVKELCKYLRPM IQEYVDVFGDNVITHQRFEGVGVMDEKDCISYGV TGPAGRASGWKNDVRKYHPYAMYDKVNFEEITLT NGDSMDRYFCHIKEIYQSLNIIEQLIDNIPEGEF YIKQKPIIKVPEGQWYFSVEGASGEFGAYLDSRG DKTAYRLKFRPMGLTLVGAMDKMLRGQKIADLVT TGAALDFVIPDIDR 10 FKBP- P45523 MRTSTQSKDMGKKQEYKLRNEEFLHNISKKDSIK type_peptidyl- TLPHGIFYEIIKEGSGEGTVQPRSIVICNYRGSL prolyl_cis- ISGQVFDDSWQKPTPEAFRLNELITGLQIALCAM trans_isomerase HKGDSWRIYIPYQEGYGSKRNADIPAFSTLIFDI ELINIA 11 Putative_acetolactate_ P9WKJ3 MADNKIAKESVKREVIAGERLYTLLVYSENVAGV synthase_small_ LNQIAAVFTRRQVNIESLNVSASSIEGIHKYTIT subunit AWSDAATIEKITKQVEKKIDVIKADYYEDSDLFI HEVGLYKIATPILLENAEVSRAIRKRNARMMEVN PTYSTVLLAGMTDEVTALYHDLKNFDCLLQYSRS GRVAVTRGFSEPVSDFLKSEEESSVL 12 Serine/threonine_ P0AGE4 MKKKVKIGLLPRVIIAILLGIFFGYFMPTPLARV transporter_SstT FLTFNGIFSQFLGFMIPLIIIGLVTPAIADIGKG AGKLLLVTVIIAYVDTVVAGGLAYGTGLCLFPSM IASTGGAMPHIDKATELAPYFSINIPAMADVMSG LVFSFMLGLGIAYGGLTATKNIFNEFKYVIEKVI AKAIIPLLPLYIFGVFLNMAHNGQAQQILLVFSQ IIIVILVLHVFILVYQFCIAGAIIRRNPFRLLWN MMPAYLTALGTSSSAATIPVTLEQTMKNGVGKEI AGFVVPLCATIHLSGSAMKITACALTICLLVGLP HDPALFIYFILMLSIIMVAAPGVPGGAIMAALAP LASILGFNSEAQALMIALYIAMDSFGTACNVTGD GAIALVVNKMFGKKER 13 Cluster: G6AJ07 MKKLLLLVCAAVMSLSASAQAGDKALGAQLVFGS Uncharacterized ETNSLGFGVKGQYYFTDHIRGEGSFDYFLKNKGI protein SMWDINANVHYLFDVADKFKVYPLAGLGYTNWSY KYEYAGAPVVEGSDGRLAVNLGGGVEYELTKNLN VNAEAKYQIISNYNQLVLGVGVAYKF 14 Heterocyst_ P22638 MHFYCTKSSLDTMSERYVKRMIAKLASQGKTVIS differentiation_ATP- IAHRFSTIMDAKHIILLAKGKVVAEGTHQELLKT binding_protein SEDYRKLWSDQNDEID 15 UDP-2,3- Q9I2V0 MKNVYFLSDAHLGSLAIAHRRTQERRLVRFLDSI diacylglucosamine_ KHKASAVYLLGDMFDFWDEYKYVVPKGFTRFLGK hydrolase VSELTDMGVEVHFFTGNHDLWTYGYLEEECGVIL HRKPVTMEIYGKVFYLAHGDGLGDPDPMFQFLRK VFHNRVCQRLLNFFHPWWGMQLGLNWAKKSRLKR ADGKEMPYLGEDKEYLVRYTKDYMRSHKDIDYYI YGHRHIELDLTLSGKVRMLILGDWIWQFTYAVFD GEHMFLEEYIEGESKP 16 Anaerobic_glycerol- P0A9C0 MNSKQNDNYDVIIIGGGITGAGTARDCALRGLKV 3-phosphate_ LLVEKFDFTNGATGRNHGLLHSGARYAVTDPESA dehydrogenase TECIKENMVLRRIAKHCIEETDGLFITLPEDDIN YQKTFVEACARAGISANIISPEEALRLDPSVNPD LLGAVRVPDASVDPFHLTTANVLDARQHGADVLT YHEVVAILTSNGRVEGVRLRNNHTGEEIEKHAVL VINAAGIWGHDIAKMADIKINMFPAKGTLLVFGH RVNKMVINRCRKPANADILVPDDAVCVIGTTSDR VPYDTVDNLKITSEEVDTLIREGEKLAPSLATTR ILRAYAGVRPLVAADNDPTGRSISRGIVCLDHEK RDGLTGMITITGGKMMTYRLMAEQATDLACKKLG INKTCETATTPLPGTAGKDSDNPHHTYSTAHKAA KGRQGNRVKEIDERTEDDRALICECEEVSVGEAK YAIEELHVHDLLNLRRRTRVGMGTCQGELCACRA AGVMCENGVKVDKAMTDLTKFINERWKGMRPVAW GSTLDEAQLTTIIYQGLCGLGI 17 Anaerobic_glycerol- P13033 MRYDTIIIGGGLSGLTAGITLAKAGQKVCIVSAG 3-phosphate_ QSSLHFHSGSFDLLGYDADGEVVTHPLQAIADLK dehydrogenase AEHPYSKIGISNIEHLASQAKTLLCEAGISVMGN YEQNHYRVTPLGTLKPAWLTTEGYAMIDDPEILP WKKVELLNIQGFMDFPTQFIAENLRMMGVECQIK TFTTDELSTARQSPTEMRATNIAKVLANKDALSK VSERINAISGDPDALLLPAVLGFSNAESLDEMKQ WIKKPVQYIATLPPSVSGVRTTILLKRLFAQAGG TLLIGDSATTGQFSGNHLVSITTDHLPDEKLYAD HFILASGSFMSHGIRSNYAGVYEPVFKLDVDAAE KRDDWSVTNAFEAQPYMEFGVHTDKDFHATKDGK NIENLYAIGSVLSGHNSIKHADGTGVSLLTALYV AKKITGKG 18 Anaerobic_glycerol- P0A996 MAEGIQLKNISGNNLEQCLKCSICTAYCPVSAVE 3-phosphate_ PKYPGPKQSGPDQERYRLKDSKFFDEALKMCLNC dehydrogenase KRCEVACPSGVRIADIIQASRITYSTHRPIPRDI MLANTDFVGTMANMVAPIVNATLGLKPVKAVLHG VMGIDKHRTFPAYSSQKFETWYKRMAAKKQDSYS KHVSYFHGCYVNYNFPQLGKDLVKIMNAVGYGVH LLEKEKCCGVALIANGLSGQARRQGKVNIRSIRK AAEQNRIVLTTSSTCTFTMRDEYEHLLDIKTDDV RENITLATRFLYRLIEKGDIKLAFRKDFKMRTAY HSACHMEKMGWIIYSTELLKMIPGLELIMLDSQC CGIAGTYGFKKENYQRSQEIGEGLFKQIKELNPD CVSTDCETCKWQIEMSTGYEVKNPISILADALDV EETIKLNQ 19 Glycerol_uptake_ P18156 MMIKNIVLSIPISLIIYLNHLIMEYSMTTQFLME facilitator_protein LIGTLILVLFGDGVCACVTLNKSKGQKAGWVVIT IAWGLAVCMGVLVAGPYTGAHLNPAVSIGLAVAG MFPWSSVPYYIVAQMIGGFLGGLLVWFFYKDHYD ATDDEAAKLGTFCTSPAIRNYKMNFLSEVIATLV LVFIIISFSVDGNTGDAEHFKFGLAALGPIPVTL LIIALGMSLGGTTGYAMNPARDLSPRLAHAVCMK GDNDWSYSWIPVLGPIIGAIIAGFCGAALLLV 20 Serine/threonine- Q97PA9 MSEKIIPSNEPAQAASEPIKASYTEYTVIPSQGY protein_kinase_StkP CQFVKCKKGDQPVVLKGLKEAYRERVLLRNALKR EFKQCQRLNHPGIVRYQGLVDVEGYGLCIEEEYV DGRTLQAYLKESHTDDEKITIVNQIADALRYAHQ QGVAHRNLKPSNILITKQGDHVKLIDFNVLSLDD VKPTADTTRFMAPELKDETMTADGTADIYSLGTI MKVMGLTLAYSEVIKRCCAFKRSDRYSDIDEFLA DFNHDGSSFSMPKIGKGTVVIGFIAVVVIALAAL AYNYGGALVDQVGKIDVTSIFKSDAETAPEDSAM VKSVEQNNNDSVADEAPATGKLAFMNTMKPALYK DLDRLFAKHSDDRAKLNRAIKVYYRGLIQANDTL DNEQRAELDRVFGNYVKQKKAALK 21 Cluster: D-alanyl- G6AHI1 MLVAQLFVGVLQAQKPVQNRRQAVGQSMERQGLV D-alanine dipeptidase NVKAVVPSIKVALMYARTDNFCHRMALS 22 Anaerobic_C4- P0ABN5 MITGLVIIQLLIVLALIFIGARVGGIGLGIYGMI dicarboxylate_ GVFILVYGFGLAPGSAPIDVMMIIVAVITAASAL transporter_DcuA QASGGLEYLVGVAAKFLQKHPDHITYFGPITCWL FCVVAGTAHTSYSLMPIIAEIAQTNKIRPERPLS LSVIAASLGITCSPVSAATAALISQDLLGAKGIE LGTVLMICIPTAFISILVAAFVENHIGKELEDDP EYKRRVAAGLINPEAACEEVQKAENEHDPSAKHA VWAFLFGVALVILFGFLPQLRPEGVSMSQTIEMI MMSDAALILLVGKGKVGDAVNGNIFKAGMNAVVA IFGIAWMGNTFYVGNEKILDAALSSMISSTPILF AVALFLLSIMLFSQAATVTTLYPVGIALGINPLL LIAMFPACNGYFFLPNYPTEVAAIDFDRTGTTRV GKYVINHSFQIPGFITTIVSILLGVLMVQFFR 23 L-asparaginase_2 P00805 MRILKITFVTVLALVMSTVVFAQKPKIRIIATGG TIAGVSASATSSAYGAGQVGVQTLIDAVPQIKDI ADVSGEQLVNIGSQDMNDEVWLKLAKRINDLLNK EGYDGVLITHGTDTMEETAYFLSLTVHTDKPVVM VGSMRPSTAISADGPANLYNGICTLVDPSSKGHG VMVCMNNELFEAKSVIKTHTTDVSTFKGGLYGEM GYVYNGKPYFLHKPVAKQGLTSEFNVDNLTSLPK VGIVYGYANCSPLPIQAFVNAKFDGIVLAGVGDG NFYKDVFDVALKAQNSGIQIVRSSRVPFGPTNLN GEVDDAKYHFVASLNLNPQKARVLLMLALTKTKD WQKIQQYFNEY 24 Trehalose_synthase/ P9WQ19 MALACAMTMSASAQMGTNPKWLGDAIFYQIYPSS amylase_TreS YMDTDGNGIGDLPGITQKLDYIKSLGVNAIWLNP VFESGWFDGGYDVIDFYKIDPRFGTNTDMVNLVK EAHKRGIKVCLDLVAGHTSTKCPWFKESANGDRN SRYSDYFIWTDSISEADKKEIAERHKEANPASST HGRYVEMNAKRGKYYEKNFFECQPALNYGFAKPD PNQPWEQPVTAPGPQAVRREMRNIMAFWFDKGVD GFRVDMASSLVKNDWGKKEVSKLWNEMREWKDKN YPECVLISEWSDPAVAIPAGFNIDFMIHFGIKGY PSLFFDRNTPWGKPWPGQDISKDYKFCYFDKAGK GEVKEFVDNFSEAYNATKNLGYIAIPSANHDYQR PNIGTRNTPEQLKVAMTFFLTMPGVPFIYYGDEI GMKYQMDLPSKEGSNERAGTRTPMQWTSGPTAGF STCNPSQLYFPVDTEKGKLTVEAQQNDPRSLLNY TRELTRLRHSQPALRGNGEWILVSKESQPYPMVY KRTSGGETVVVAINPSDKKVSANIAHLGKAKSLI MTGKASYKTGKTEDAVELNGVSAAVFKIAE 25 Ribitol-5- Q720Y7 MNIAVIFAGGSGLRMHTKSRPKQFLDLNGKPIII phosphate_cytidyl- YTLELFDNHPGIDAIVVACIESWIPFLEKQLRKF yltransferase EINKVVKIVPGGESGQASIYNGLCAAEAYIKSKN VASEDTTVLIHDGVRPLITEETITDNINKVAEVG SCITCIPATETLVVKQHDGSLEIPSRADSLIARA PQSFLLSDILTAHRRAIDEKKNDFIDSCTMMSHY GYRLGTIIGPMENIKITTPTDFFVLRAMVKVHED QQIFGL 26 UDP-Glc: alpha-D- B5L3F2 MTEKKSVSIVLCTYNGTKYLQEQLDSILAQTYPL GlcNAc- HEIIIQDDGSTDNTWQILEKYEEKYPLIHIYHNE diphosphoundecaprenol GTHGVNANFLSAMHRTTGDFIAIADQDDIWETDK IANQMTTIGNKLLCSGLTRPFSSDGSFAYFDNRP RNVSIFRMMFLGLPGHTMLFRRELLRMMPPVTHS FFNVSLYDAALSILAASHDSIAFCNKVLVNFRRH ADATTYNDYSRSLPSWQNGLYELLWGLRHYHQAR SIALPIYRGKLALMEGITTNYHDFIEAKAIMRLE TQKGLWAFLRLQYLLTKNHQRLFQTSGGSFIKMI RAWLYPVMQLYMYHHALRRCK 27 UDP-N- P33038 MESFIIEGGHRLSGTIAPQGAKNEALEVICATLL acetylglucosamine TTEEVIIRNIPNILDVNNLIKLLQDIGVKVKKLG ANDFSFQADEVKLDYLESIDFVKKCSSLRGSVLM IGPLLGRFGKATIAKPGGDKIGRRRLDTHFLGFK NLGARFVRIEDRDVYEIQADKLVGDYMLLDEASV TGTANIIMSAVMAEGTTTIYNAACEPYIQQLCHL LNAMGAKITGIASNLITIEGVTSLHGAEHRILPD MIEVGSFIGMAAMVGDGVRIKDVSIPNLGLILDT FRRLGVQIIEDEDDLIIPRQDHYVIDSFIDGTIM TISDAPWPGLTPDLISVLLVVATQAQGSVLFHQK MFESRLFFVDKLIDMGAQIILCDPHRAVVVGHDH AKKLRAGRMSSPDIRAGIALLIAALTAEGTSRID NIAQIDRGYENIEGRLNALGAKVQRVEIC 28 Sensor_protein_EvgS P30855 MERSGNFYKAIRLGYILISILIGCMAYNSLYEWQ EIEALELGNKKIDELRKEINNINIQMIKFSLLGE TILEWNDKDIEHYHARRMAMDSMLCRFKATYPAE RIDSVRHLLEDKERQMCQIVQILEQQQAINDKIT SQVPVIVQKSVQEQPKKSKRKGFLGIFGKKEEAK PTVTTTMHRSFNRNMRTEQQAQSRRLSVHADSLA ARNAELNRQLQGLVVQIDGKVQTDLQKREAEITA MRERSFIQIGGLTGFVILLLVISYIIIHRNANRI KRYKQETADLIERLQQMAKRNEALITSRKKAVHT ITHELRTPLTAITGYAGLIQKNFNADKTGMYIRN IQQSSDRMREMLNTLLSFFRLDDGKEQPNFSTCR ISSIAHTLESEFMPIAINKGLALTVTNHTDAVVL TDKERILQIGNNLLSNAIKFTENGAVSLTMGYDN GMLKLIVKDTGSGMTEEEQQRVFGAFERLSNAAA KDGFGLGLSIVQRIVTMLGGTIQLKSEKGKGSRF TVEIPMQSAEELPERINKTQIHHNRTLHDIVAID NDKVLLLMLKEMYAQEGIHCDTCTNAAELMEMIR RKEYSLLLTDLNMPDINGFELLELLRTSNVGNSR IIPIIVTTASGSCNREELLERGFSDCLLKPFSIS ELMEVSDKCAMKGKQNEKPDFSSLLSYGNESVML DKLIAETEKEMQSVRDGEQRKDFQELDALTHHLR SSWEILRADQPLRELYKQLHGSAVPDYEALNNAV TAVLDKGSEIIRLAKEERRKYENG 29 Phosphate- Q7A5Q2 MKRSRFYITVGLILSLTLLMSACGQKKAKDGRTD binding_protein_PstS TPTSGTIKFASDESFSPIVEELLQNYQFRYPQAH LLPIYTDDNTGMKLLLDQKVNLFITSHAMTKGED AILRGKGPIPEVFPIGYDGIAFIVNRSNPDSCIT VDDVKKILQGKIAKWNQLNPKNNRGSIEVVFDNK ASATLHYVVDSILGGKNIKSENIVAAKNSKSVID YVNKTPNAIGVIGSNWLNDHRDTTNTTFKKDVTV ASISKATVASPSNSWQPYQAYLLDGRYPFVRTIY ALLADPHKALPYAFANYIANPIGQMIIFKAGLLP YRGNINIREVEVKNQ 30 Bifunctional_purine_ P9WHM7 MAGTKRIKTALISVFHKDGLDDLLKKLDEEGVQF biosynthesis_protein_ LSTGGTQQFIESLGYECQKVEDVTSYPSILGGRV PurH KTLHPKIFGGILARRDNEEDQKQMVEYTIPAIDL VIVDLYPFEQTVASGASAQDIIEKIDIGGISLIR AGAKNFKDVVIVPSKAEYPVLLQLLNTKGAETEI EDRKMFAERAFGVSSHYDTAIHSWFAAE 31 Multidrug_efflux_ P0AE06 MEEEKGGRIGQRPYILKIITERNYIIIIDMKKAK pump_subunit_AcrA ILLFVTALVAVLTSCGGGQKGLPTSDEYPVITIG ASNAQLKTTYPATIKGVQDVEVRPKVSGFITKLN IHEGEYVHAGQVLFVIDNSTYQAAVRQAQAQVNS AQSAVAQAKANVVQANASLNSANAQAATSRLTYN NSQNLYNNKVIGDYELQSAKNTYETAQASVRQAQ SGIASAQAAVKQAEAGVRQAQAMLSTAKDNLGFC YVKSPASGYVGSLPFKEDALVSASSAQPVTTISN TSTIEVYFSMTEADVLKLSRTDDGLSNAIKKFPA VSLLLADGSTYNHEGAIVKTSGMIDATTGTINVI ARFPNPEHLLKSGGSGKIVIAKNNNRALLIPQEA VTQVQNKMFVYKVDAKDKVHYSEITVDPQNDGIN YIVTSGLKMGERIVSKGVSSLEDGAKIKALTPAE YEEAIKKAEKLGENQSSASGFLKTMKGDSK 32 Cell_division_protein_ Q81X30 MAKRRNKARSHHSLQVVTLCISTAMVLILIGMVV FtsX LTVFTSRNLSSYVKENLTVTMILQPDMSTEESAA LCQRIRSLHYINSLNFISKEQALKEGTRELGANP AEFAGQNPFTGEIELQLKANYANNDSIKNIEREL RTYRGVSDITYPQNLVESVNHTLGKISLVLLVIA ILLTIVSFSLMNNTIRLSIYARRFSIHTMKLVGA SWGFIRAPFLRRAVMEGLVSALLAIAVLGVGLCL LYDYEPDITKVLSWDVLVITAGVMLAFGVLIATF CSWLSVNKFLRMKAGDLYKI 33 Fe(2+)_transporter_ Q9PMQ9 MKLSDLKTGETGVIVKVLGHGGFRKRIIEMGFIQ FeoB GKQVEVLLNAPLRDPVKYKIMGYEVSLRHSEADQ IEVISAEEARQLEQAKADNEPQQGALSNNIPDES DHALTPFELTDAANRKSKVINVALVGNPNCGKTS LFNFASGAHERVGNYSGVTVDAKVGRANYEGYEF HLVDLPGTYSLSAYSPEELYVRKQLVEKTPDVVI NVIDASNLERNLYLTTQLIDMHVRMVCALNMFDE TEQRGDNIDYQKISELFGIPMVPTVFTNGRGVKE LFHQVIAVYEGKEDETSQFRHIHINHGHELEGGI KNIQEHLRAYPDICQRYSTRYLAIKLLEHDKDVE ELIKPLKDSDEIFKHRDIAAQRVKEETGNESETA IMDAKYGFIHGALEEADYSTGQKKDTYQTTHFID QILTNKYFGFPIFFLILFIMFTATFVIGQYPMDW IDGGVSWLGDFISSNMPDGPVKDMLVDGIIGGVG AVIVFLPQILILYFFISYMEDSGYMARAAFIMDK LMHKMGLHGKSFIPLIMGFGCNVPAVMATRTIES RRSRLVTMLILPLMSCSARLPIYVMITGSFFALK YRSLAMLSLYVIGILMSVIMSRVFSRFLVKGEDT PFVMELPPYRFPTWKAIGRHTWEKGKQYLKKMGG IILVASIIVWALGYFPLPDKPDMGQQERQEHSFI GQIGHAVEPVFRPQGFNWKLDVGLLAGVGAKEIV ASTMGVLYSNDDSFKDDNSFSSEGGKYVKLHKQI TQDVANLHGVSYNEAEPIATLTAFCFLLFVLLYF PCIATIAAIKGETGSWGWALFAAGYTTLLAWVVS AIVFQVGMLFIG 34 Pneumolysin Q04IN8 MKKNLLKAVLPASLALFAVTFGSCSQDGQLTGTK EDTGERVLDNTREIQNYLRTLPLAPMMSRASDPV PSDDGTTVPVDEGTSKTEEKGVLNGIPGSWVKTT RRYKMTQAFDESFLFDPTSDIVYPGCVLKGGTIA NGTYAIITSHETGDVTFSINLSPANPQEARETSA TVHNIRKSEYQEVWNKWANMQWKESPITTIESVE KINSQEELATKLGVAVNSPVANGSLNFGFNFNKK KNHILARLIQKYFSVSTDAPKKGNIFESIDKEAL DGYQPVYISNINYGRIIYLSVESDEDEKVVDEAI NFAMNQIKGVDVSVSADQSLHYRKVLANCDIRIT VLGGGQTIQKEVLKGDIDSFQRFLNADIPMEQMS PISFSLRYAVDNSQARVVTSNEFTVTQRDFVPEF KKVRMQLQVLGFSGTNTGPFPNLDREAGLWGSIS LSLNGQDNELVKISQSNPFFFNYREKKETMHPIG FGGIVTVEFDKDPNESLEDFVDHQKMTFVSDLHS TRSIYNYNFGRTTFTHTLGTLYTKYKGDDPIFVL ESNNKNVKIHTYVKVLDMKFFN 35 Cluster: G6AG77 MTKFIYAMSLFLLAAISIKAQPIQKTSGCLLHGS Uncharacterized VVSSTDATAIAGATVRLYQLKKLVGGTVSDASGN protein FDVKCPSSGSLQLRITAVGFKEVDTTLNVPTVTP LSIYMRAGKHAMDEVTVTASEKRGMTSTTVIGQT AMEHLQPSSFADLLALLPGGMTKIPALGSANVIT LREAGPPSSQYATSSLGTKFVIDGQAIGTDANMQ YIAGSFQGDADNSRNHVSYGVDMREIPTDNIEKV EVVRGIPSVKYGELTSGLINITRKRSQSPLLLRL KADEYGKLVSVGKGFLLSGKWNLNVDGGLLDARK EPRNRFETYRRLTFSARLRRKWNLGERYVLEWSG ATDYSLNIDNVKTDPEIQIHREDSYRSSYLKMGM NHRLLLRRKALVGLQSVSLAYSASLASDRIHQTE AVALQRDYVVPLAYEGGEYDGLFLPMQYLCDYRV EGKPFYSTLRGETEWLARTSFISHHITAGGEFLL NKNYGRGQIFDITKPLHASTARRPRSYKDIPATD ILSFYAEDKATMPIGKHQLTVMAGLRTTQMLNIP ASYAVHGKLFTDTRVNVQWDFPSFLGFKSFVSGG LGMMTKMPTVLDLYPDYVYKDITEMNYWDIRPAY KRIHIRTYKLNQVNPDLRPARNKKWEIRLGMDKG AHHFSVTYFHEDMKDGFRSTTTMRPFIYKRYDTS VINPSALTGPPSLASLPVVTDTLLDGYGRTENGS RITKQGIEFQYSSPRIPVIQTRITVNGAWFRTLY ENSIPLFRSAPNVVVGTVAIADRYAGYYMSTDKY DKQIFTSNFIFDSYVDKLGLILSATAECFWMSNT KRPATSSTPMGYMDITGTVHPYVEADQSDPYLRW LVLTGTAGQDMDYRERSYMLVNFKATKRFGRHLS LSFFADRVFYVAPDYEVNGFIVRRTFSPYFGMEI GLKI 36 Cell_division_ATP- P0A9R7 MLIDFKKVNIYQDERLILKDIDFQATEGEFIYLI binding_protein_FtsE GRVGSGKSSLLKTFYGELDIDQEDAEKAEVLGES VLDIKQKRIPALRRQMGIIFQDFQLLHDRSVAKN LKFVLQATGWKDKEKIKQRIKEVLEQVGMIDKAA KMPSELSGGEQQRIAIARAFLNNPKIILADEPTG NLDPETASNIVSILKDTCKNGTTVIMSTHNINLL SQFPGKVYRCMEQALVPVTNEAQTKDLEEDSTSV EPLIEPVLEEEAQAEDSKE 37 Di-/tripeptide_ P0C2U3 MFENQPKALYALALANTGERFGYYTMIAVFALFL transporter RANFGLEPGTAGLIYSIFLGLVYFLPLIGGIMAD KFGYGKMVTIGIIVMFAGYLFLSVPLGGGTVAFG AMLAALLLISFGTGLFKGNLQVMVGNLYDTPELA SKRDSAFSIFYMAINIGALFAPTAAVKIKEWAET SLGYAGNDAYHFSFAVACVSLIVSMGIYYAFRST FKHVEGGTKKTEKAAAAAVEELTPQQTKERIVAL CLVFAVVIFFWMAFHQNGLTLTYFADEFVSPTST GVQSMAFDVVNLVMIVFIVYSIMALFQSKTTKAK GIACAVILAAIAVLAYKYMNVNGQVEVSAPIFQQ FNPFYVVALTPISMAIFGSLAAKGKEPSAPRKIA YGMIVAGCAYLLMVLASQGLLTPHEQKLAKAAGE TVPFASANWLIGTYLVLTFGELLLSPMGISFVSK VAPPKYKGAMMGGWFVATAIGNILVSVGGYLWGD LSLTVVWTVFIVLCLVSASFMFLMMKRLEKVA 38 Calcium- Q47910 MKKILIFVAGLCMSLAASAQIQRPKLVVGLVVDQ transporting_ATPase MRWDYLYYYYNEYGTDGLRRLVDNGFSFENTHIN YAPTVTAIGHSSVYTGSVPAITGIAGNYFFQDDK NVYCCEDPNVKSVGSDSKEGQMSPHRLLASTIGD ELQISNDFRSKVIGVALKDRASILPAGHAADAAY WWDTSAGHFVTSTFYTDHLPQWVIDFNEKNHTAP NFNIKTSTQGVTMTFKMAEAALKNENLGKGKETD MLAVSISSTDAIGHVYSTRGKENHDVYMQLDKDL AHFLKTLDEQVGKGNYLLFLTADHGAAHNYNYMK EHRIPAGGWDYRQSVKDLNGYLQGKFGIAPVMAE DDYQFFLNDSLIAASGLKKQQIIDESVEYLKKDP RYLYVFDEERISEVTMPQWIKERMINGYFRGRSG EIGVVTRPQVFGAKDSPTYKGTQHGQPFPYDTHI PFLLYGWNVKHGATTQQTYIVDIAPTVCAMLHIQ MPNGCIGTARNMALGN 39 Poly-beta-1,6-N- Q5HKQ0 MDRQVFQTDSRQRWNRFKWTLRVLITIAILLGVV acetyl-D- FVAMFALEGSPQMPFRHDYRSVVSASEPLLKDNK glucosamine_synthase RAEVYKSFRDFFKEQKMHSNYAKVAARQHRFVGH TDNVTQKYIKEWTDPRMGIRSAWYVNWDKHAYIS LKNNLKNLNMVLPEWYFINPKTDRIEARIDQRAL KLMRRAHIPVLPMLTNNYNSAFRPEAIGRIMRDS TKRMGMINELVAACKHNGFAGINLDLEELNINDN ALLVTLVKDFARVFHANGLYVTQAVAPFNEDYDM QELAKYDDYLFLMAYDEYNAGSQAGPVSSQRWVE KATDWAAKNVPNDKIVLGMATYGYNWAQGQGGTT MSFDQTMATALNAGAKVNFNDDTYNLNFSYQDED DGTLHQVFFPDAVTTFNIMRFGATYHLAGFGLWR LGTEDSRIWKYYGKDLSWESAARMPIAKIMQLSG TDDVNFVGSGEVLNVTSEPHAGRIGIVLDKDNQL IIEERYLSLPATYTVQRLGKCKEKQLVLTFDDGP DSRWTPKVLSILKHYKVPAAFFMVGLQIEKNIPI VKDVFNQGCTIGNHTFTHHNMIENSDRRSFAELK LTRMLIESITGQSTILFRAPYNADADPTDHEEIW PMIIASRRNYLFVGESIDPNDWQQGVTADQIYKR VLDGVHQEYGHIILLHDAGGDTREPTVTALPRII ETLQREGYQFISLEKYLGMSRQTLMPPIKKGKEY YAMQANLSLAELIYHISDFLTALFLVFLVLGFMR LVFMYVLMIREKRAENRRNYAPIDPLTAPAVSII VPAYNEEVNIVRTISNLKEQDYPSLKIYLVDDGS KDNTLQRVREVFENDDKVVIISKKNGGKASALNY GIAACSTDYIVCVDADTQLYKDAVSKLMKHFIAD KTGKLGAVAGNVKVGNQRNMLTYWQAIEYTTSQN FDRMAYSNINAITVIPGAIGAFRKDVLEAVGGFT TDTLAEDCDLTMSINEHGYLIENENYAVAMTEAP ESLRQFIKQRIRWCFGVMQTFWKHRASLFAPSKG GFGMWAMPNMLIFQYIIPTFSPIADVLMLFGLFS GNASQIFIYYLIFLLVDASVSIMAYIFEHESLWV LLWIIPQRFFYRWIMYYVLFKSYLKAIKGELQTW GVLKRTGHVKGAQTIS 40 ATP_synthase_subunit_ P29707 MSQINGRISQIIGPVIDVYFDTKGENPEKVLPNI beta,_sodium_ion_ YDALRVKKADGQDLIIEVQQQIGEDTVRCVAMDN specific TDGLQRGLEVVPTGSPIVMPAGEQIKGRMMNVIG QPIDGMSALQMEGAYPIHREAPKFEDLSTHKEML QTGIKVIDLLEPYMKGGKIGLFGGAGVGKTVLIM ELINNIAKGHNGYSVFAGVGERTREGNDLIRDML ESGVIRYGEKFRKAMDEGKWDLSLVDSEELQKSQ ATLVYGQMNEPPGARASVALSGLTVAEEFRDHGG KNGEAADIMFFIDNIFRFTQAGSEVSALLGRMPS AVGYQPTLASEMGAMQERITSTKHGSITSVQAVY VPADDLTDPAPATTFTHLDATTELSRKITELGIY PAVDPLGSTSRILDPLIVGKEHYDCAQRVKQLLQ KYNELQDIIAILGMDELSDDDKLVVNRARRVQRF LSQPFTVAEQFTGVKGVMVPIEETIKGFNAILNG EVDDLPEQAFLNVGTIEDVKEKAKQLLEATKA 41 Cluster: G6AGX5 MNPIYKIITSILFCVLSINTMAQDLTGHVTSKAD Uncharacterized DKPIAYATVTLKENRLYAFTDEKGNYTIKNVPKG protein KYTVVFSCMGYASQTVVVMVNAGGATQNVRLAED NLQLDEVQVVAHRKKDEITTSYTIDRKTLDNQQI MTLSDIAQLLPGGKSVNPSLMNDSKLTLRSGTLE RGNASFGTAVEVDGIRLSNNAAMGETAGVSTRSV SASNIESVEVVPGIASVEYGDLTNGVVKVKTRRG SSPFIVEGSINQHTRQIALHKGVDLGGNVGLLNF SIEHARSFLDAASPYTAYQRNVLSLRYMNVFMKK SLPLTLEVGLNGSIGGYNSKADPDRSLDDYNKVK DNNVGGNIHLGWLLNKRWITNVDLTAAFTYADRL SESYTNESSNATQPYIHTLTEGYNIAEDYDRNPS ANIILGPTGYWYLRGFNDSKPLNYSLKMKANWSK AFGKFRNRLLVGGEWTSSMNRGRGTYYADMRYAP SWREYRYDALPSLNNIAIYAEDKLSMDVNERQNA ELTAGIREDITSIPGSEYGSVGSFSPRMNARYVF RFGQNSWLNSMTLHAGWGRSVKIPSFQVLYPSPS YRDMLAFASTSDADNRSYYAYYTYPSMARYNANL KWQRADQWDLGVEWRTKIADVSLSFFRSKVSNPY MATDVYTPFTYKYTSPAMLQRSGIAVADRRFSID PQTGIVTVSDASGVKSPVTLGYEERNTYVTNTRY VNADALQRYGLEWIVDFKQIKTLRTQVRLDGKYY HYKAQDETLFADVPVGLNTRQSDGRLYQYVGYYR GGAATTTNYTANASASNGSVSGQVDLNATITTHI PKIRLIVALRLESSLYAFSRATSSRGYVVSSGNE YFGVPYDDKTENQTVIVYPEYYSTWDAPDVLIPF AEKLRWAETNDRGLFNDLAQLVVRTNYPYTLNPN RLSAYWSANLSVTKEIGRHVSVSFYANNFFNTLS QVHSTQTGLETSLFGSGYVPSFYYGLSLRLKI

    [0103] In some embodiments, the Prevotella bacteria is a strain of Prevotella bacteria free or substantially free of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more) proteins listed in Table 2 and/or one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more) genes encoding proteins listed in Table 2. In some embodiments, Prevotella bacteria is free of all of the proteins listed in Table 2 and/or all of the genes encoding the proteins listed in Table 2.

    TABLE-US-00002 TABLE 2 Other Prevotella proteins Seq. ID. No. Name Uniprot ID Amino Acid Sequence 42 UDP-Gal: alpha-D- Q03084 MERIDISVLMAVYKKDNPAFLRESLESIFSQTVEAAEV GlcNAc- VLLEDGPLTDALYDVIKSYEAIYSTLKVVSYPENRGLG diphosphounde- KTLNDGLLLCKYNLVARMDADDICKPNRLEMEYNWLKS caprenol HEDYDVIGSWVDEFTDNKTRVKSIRKVPEAYDEIKNYA QYRCPINHPTAMYRKAAVLAVGGYLTEYFPEDYFLWLR MLNNGSKFYNIQESLLWFRYSEETVAKRGGWAYACDEV RILVRMLKMGYIPFHVFCQSVVIRFTTRVMPLPIRQRL YNLIRKT 43 ATP_synthase_ A1B8P0 MSQINGRISQIIGPVIDVYFDTKGENPEKVLPKIHDAL subunit_beta RVKRANGQDLIIEVQQHIGEDTVRCVAMDNTDGLQRNL EVVPTGSPIVMPAGDQIKGRMMNVIGQPIDGMEALSME GAYPIHREAPKFEDLSTHKEMLQTGIKVIDLLEPYMKG GKIGLFGGAGVGKTVLIMELINNIAKGHNGYSVFAGVG ERTREGNDLIRDMLESGVIRYGEKFRKAMDEGKWDLSL VDQEELQKSQATLVYGQMNEPPGARASVALSGLTVAEE FRDHGGKNGEAADIMFFIDNIFRFTQAGSEVSALLGRM PSAVGYQPTLASEMGTMQERITSTKHGSITSVQAVYVP ADDLTDPAPATTFTHLDATTELSRKITELGIYPAVDPL GSTSRILDPLIVGKDHYECAQRVKQLLQHYNELQDIIA ILGMDELSDEDKLVVNRARRVQRFLSQPFTVAEQFTGV KGVMVPIEETIKGFNAILNGEVDDLPEQAFLNVGTIED VKEKAKRLLEATK 44 Cell_division_ O05779 MPIGNGQKYQLTIINHTEIIMLIDYKKVNIYQDERLIL ATP-binding_ KDVDFQAETGEFIYLIGRVGSGKSSLLKTIYGELDIDS protein_FtsE EDAEKAVVLDESMPNIKRSRIPALRKQMGIIFQDFQLL HDRSVAKNLKFVLQATGWTSKQKIERRIEEVLAQVGMT DKKNKMPSELSGGEQQRIAIARALLNTPKIIIADEPTG NLDPETAANIVSILKDSCQAGTTVIMSTHNINLIDQFP GKVYRCHEGELHQLTDKKEVSELAEETAPVETIDEPEQ ND 45 Hemin_transport_ Q56992 MKRNILLFICLATSILLLFGLNLTTGSVQIPFADILDI system_permease_ LCGRFIGKESWEYIILENRLPQTLTAILCGASLSVCGL protein_HmuU MLQTAFRNPLAGPDVFGISSGAGLGVALVMLLLGGTVS TSIFTVSGFLAILTAAFVGAIAVTALILFLSTLVRNSV LLLIVGIMVGYVSSSAVSLLNFFASEEGVKSYMVWGMG NFGAVSMNHIPLFSILCLIGIIASFLLVKPLNILLLGP QYAESLGISTRQIRNILLVVVGLLTAITTAFCGPISFI GLAIPHIARLLFRTENHQILLPGIVLSGAAIALLCNFI CYLPGESGIIPLNAVTPLIGAPIIIYVIIQRR 46 Hexuronate_ O34456 MKKYYPWVLVALLWFVALLNYMDRQMLSTMQEAMKVDI transporter AELNHAEAFGALMAVFLWIYGIVSPFAGIIADRVNRKW LVVGSIFVWSAVTYLMGYAESFDQLYWLRAFMGISEAL YIPAALSLIADWHEGKSRSLAIGIHMTGLYVGQAVGGF GATLAAMFSWHAAFHWFGIIGIVYSLVLLLFLKENPKH GQKSVLQGETKPSKNPFRGLSIVFSTWAFWVILFYFAV PSLPGWATKNWLPTLFANSLDIPMSSAGPMSTITIAVS SFIGVIMGGVISDRWVQRNLRGRVYTSAIGLGLTVPAL MLLGFGHSLVSVVGAGLCFGIGYGMFDANNMPILCQFI SSKYRSTAYGIMNMTGVFAGAAVTQVLGKWTDGGNLGN GFAILGGIVVLALVLQLSCLKPTTDNME 47 1,4-alpha- P9WN45 MVTKKTTTKKAPVKKTSAKTTKVKEPSHIGLVKNDAYL glucan_branching_ APYEDAIRGRHEHALWKMNQLTQNGKLTLSDFANGHNY enzyme_GlgB YGLHQTADGWVFREWAPNATEIYLVGDFNGWNEQEAYQ CHRIEGTGNWELTLPHDAMQHGQYYKMRVHWEGGEGER IPAWTQRVVQDEASKIFSAQVWAPAEPYVWEKKTFKPQ TSPLLIYECHIGMAQDEEKVGTYNEFREKVLPRIIKDG YNAIQIMAIQEHPYYGSFGYHVSSFFAASSRFGTPEEL KALIDEAHKNGIAVIMDIVHSHAVKNEVEGLGNLAGDP NQYFYPGERHEHPAWDSLCFDYGKDEVLHFLLSNCKYW LEEYHFDGFRFDGVTSMLYYSHGLGEAFCNYADYFNGH QDDNAICYLTLANCLIHEVNKNAVTIAEEVSGMPGLAA KFKDGGYGFDYRMAMNIPDYWIKTIKELPDEAWKPSSI FWEIKNRRSDEKTISYCESHDQALVGDKTIIFRLVDAD MYWHFRKGDETEMTHRGIALHKMIRLATIAAINGGYLN FMGNEFGHPEWIDFPREGNGWSHKYARRQWNLVDNEEL CYHLLGDFDRKMLEVITSEKKFNETPIQEIWHNDGDQI LAFSRGELVFVFNFSPSHSYSDYGFLVPEGSYNVVLNT DAREFGGFGFADDTVEHFTNSDPLYEKDHKGWLKLYIP ARSAVVLRKK 48 Cluster: YihY D9RW24 MKIDIERIKYFLTVGMFMKTEHSSKRRNMLIRQFQKFY family protein LTVKFFFVRDHAASTAQLSFSTIMAIVPIASMIFAIAN GFGFGQFLEKQFREMLSAQPEAATWLLKLTQSYLVHAK TGLFIGIGLMIMLYSVFSLIRTVETTFDNIWQVKDSRP ISRIVIDYTALMFLVPISIIILSGLSIYFYSFVENLNG LRFLGTIASFSLRYLVPWAILTLMFIVLYVFMPNAKVK ITKTVAPAMIASIAMLCLQAVYIHGQIFLTSYNAIYGS FAALPLFMLWILASWYICLFCAELCYFNQNLEYYECLI DTEDICHNDLLILCATVLSHICQRFANDQKPQTALQIK TETHIPIRVMTDILYRLKEVNLISENFSPTSDEVTYTP THDTNNITVGEMIARLESTPASDFALLGFSPKKAWNHD IYDRVGSIREIYLNELKSINIKELISYSEN 49 Capsule_ P19579 MMKRPSIARWKVIICLLTPILLSFSGIGDNDIDKKKST biosynthesis_ SKEVDDTLRIVITGDLLLDRGVRQKIDMAGVDALFSPT protein_CapA IDSLFHSSNYVIANLECPVTKIRERVFKRFIFRGEPEW LPTLRRHGITHLNLANNHSIDQGRNGLLDTQEQIKKAG MIPIGAGKNMEEAAEPVLISTSPRHVWVISSLRLPLEN FLYLPQKPCVSQESIDSLIMRVKRLRATDKNCYILLIL HWGWEHHFRATPQQREDAHKLIDAGADAIVGHHSHTLQ TIETYRGKPIYYGIGNFIFDQRKPMNSRACLVELSITA EKCKAKALPIEIKNCTPYLSK 50 Peptidoglycan_ B5ZA76 MILLSFDTEEFDVPREHGVDFSLEEGMKVSIEGTNRIL deacetylase DILKANNVCATFFCTGNFAELAPEVMERIKNEGHEVAC HGVDHWQPKPEDVFRSKEIIERVTGVKVAGYRQPRMFP VSDEDIEKAGYLYNSSLNPAFIPGRYMHLTTSRTWFMQ GKVMQIPASVSPHLRIPLFWLSMHNFPEWFYLRLVRQV LRHDGYFVTYFHPWEFYDLKSHPEFKMPFIIKNHSGHE LEQRLDRFIKAMKADKQEFITYVDFVNRQKK 51 Fumarate_ P0AC47 MAKNISFTIKYWKQNGPQDQGHFDTHEMKNIPDDTSFL reductase_iron- EMLDILNEELIAAGDEPFVFDHDCREGICGMCSLYING sulfur_subunit TPHGKTERGATTCQLYMRRFNDGDVITVEPWRSAGFPV IKDCMVDRTAFDKIIQAGGYTTIRTGQAQDANAILISK DNADEAMDCATCIGCGACVAACKNGSAMLFVSSKVSQL ALLPQGKPEAAKRAKAMVAKMDEVGFGNCTNTRACEAV CPKNEKIANIARLNREFIKAKFAD 52 Serine/threonine- P9WI71 MSENKLSTNEQAQTADAPVKASYTEYKVIPSQGYCMIV protein_kinase_ KCRKGDQTVVLKTLKEEYRERVLLRNALKREFKQCQRL PknH NHSGIVRYQGLVEVDGYGLCIEEEYVEGRTLQAYLKEN HTDDEKIAIINQIADALRYAHQQGVIHRNLKPSNVLVT TQGDYVKLIDFSVLSPEDVKPTAETTRFMAPEMKDETL TADATADIYSLGTIMKVMGLTLAYSEVIKRCCAFKRSD RYSNVDELLADLNNEGSSFSMPKIGKGTVVLGLIIAVV IGIGALLYNYGGALIDQVGKIDVSSVFSSDAETAPEDT VKVNTAEQSDSLSTEAEAPAIGKLAFMNRMKPALYKDL DNIFEKNSADKAKLTKAIKTYYRGLIQANDTLDNEQRA EVDRVFGDYVKQKKAALN 53 Carboxy- O34666 MRKYICLLLFYLFTFLPLSAQQGNDSPLRKLQLAEMAI terminal_ KNFYVDSVNEQKLVEDGIRGMLEKLDPHSTYTDAKETK processing_ AMNEPLQGDFEGIGVQFNMIEDTLVVIQPVVNGPSQKV protease_CtpA GILAGDRIVSVNDSTIAGVKMARIDIMKMLRGKKGTKV KLGVVRRGVKGVLTFVVTRAKIPVHTINASYMIRPNVG YIRIESFGMKTHDEFMSAVDSLKKKGMKTLLLDLQDNG GGYLQSAVQISNEFLKNNDMIVYTEGRRARRQNFKAIG NGRLQDVKVYVLVNELSASAAEIVTGAIQDNDRGTVVG RRTFGKGLVQRPFDLPDGSMIRLTIAHYYTPSGRCIQK PYTKGDLKDYEMDIEKRFKHGELTNPDSIQFSDSLKYY TIRKHRVVYGGGGIMPDNFVPLDTTKFTRYHRMLAAKS IIINAYLKYADANRQALKAQYSSFDAFNKGYVVPQSLL DEIVAEGKKEKIEPKDAAELKATLPNIALQIKALTARD IWDMNEYFRVWNTQSDIVNKAVALATGK 54 Cluster: D9RRG3 MKLTEQRSSMLHGVLLITLFACAAFYIGDMGWVKALSL Uncharacterized SPMVVGIILGMLYANSLRNNLPDTWVPGIAFCGKRVLR protein FGIILYGFRLTFQDVVAVGFPAIIVDAIIVSGTILLGV LVGRLLKMDRSIALLTACGSGICGAAAVLGVDGAIRPK PYKTAVAVATVVIFGTLSMFLYPILYRAGIFDLSPDAM GIFAGSTIHEVAHVVGAGNAMGAAVSNSAIIVKMIRVM MLVPVLLVIAFFVAKNVAERDDEAGGSRKINIPWFAIL FLVVIGFNSLNLLPKELVDFINTLDTFLLTMAMSALGA ETSIDKFKKAGFKPFLLAAILWCWLIGGGYCLAKYLVP VLGVAC 55 Cluster: Cna X6Q2J4 MNKQFLLAALWLSPLGLYAHKANGIGAVTWKNEAPKER protein B-type MIRGIDEDKTHQRFTLSGYVKDRNGEPLINATIYDLTT domain protein RQGTMTNAYGHFSLTLGEGQHEIRCSYVGYKTLIETID LSANQNHDIILQNEAQLDEVVVTTDLNSPLLKTQTGKL SLSQKDIKTEYALLSSPDVIKTLQRTSGVADGMELASG LYVHGGNGDENLFLLDGTPLYHTNHSLGLFSSFNADVV KNVDFYKSGFPARYGGRLSSVIDVRTADGDLYKTHGSY RIGLLDGAFHIGGPIRKGKTSYNFGLRRSWMDLLTRPA FAIMNHKSDNEDKLSMSYFFHDLNFKLTNIFNERSRMS LSVYSGEDRLDAKDEWHSNNSSGYNDVDIYVNRFHWGN FNAALDWNYQFSPKLFANFTAVYTHNRSTVSSSDEWRF TRPGEKEQLTLTSHGYRSSIDDIGYRAAFDFRPSPRHH IRFGQDYTYHRFQPQTYNRFDNYQTNSEAKADTIATHS YNKNVAHQLTFYAEDEMTLNEKWSLNGGVNADVFHISG KTFATLSPRLSMKFQPTERLSLKASYTLMSQFVHKIAN SFLDLPTDYWVPTTARLHPMRSWQVAAGAYMKPNKHWL LSLEAYYKRSSHILQYSSWAGLEPPAANWDYMVMEGDG RSYGVELDADYNVSNLTLHGSYTLSWTQKKFDDFYDGW YYDKFDNRHKLTLTGRWNITKKIAAFAAWTFRTGNRMT IPTQYIGLPDVPAQEQGGLTFNSSDDNTLNFAYEKPNN VILPAYHRLDIGFDFHHTTKKGHERIWNLSFYNAYCHL NSLWVRVKIDSNNQMKIRNIAFIPVIPSFSYTFKF 56 Poly-beta-1,6-N- P75905 MSKQVFQTDSRQRWSYFKWTLRVILTILSLLGIVFLAM acetyl-D- FALEGSPQMPFRHDYRNAVTAASPYTKDNKTAKLYKSF glucosamine_ RDFFKEKKMHNNYAKATIKKQRFIGKADSVTQKYFREW synthase DDPRIGVRSAWYVNWDKHAYISLKNNIKHLNMVLPEWF FINPKTDKVEYRIDKQALRLMRRTGIPVLPMLTNNYNS DFHPEAIGRIMRDEKKRMALINEMVRTCRHYGFAGINL DLEELNIQDNDLLVELLKDFSRVFHANGLYVTQAVAPF NEDYNMQELAKYNDYLFLMAYDEHNIESQPGAVSSQRW VEKATDWAAKNVPNDKIVLGMATYGYDWANGEGGTTVS FDQTMAIAQDADAKVKFDDDTYNVNFSYQNTDDGKIHH VFFTDAATTFNIMRFGAEYHLAGYGLWRLGTEDKRIWR FYGKDMSWENVARMSVAKLMQLNGTDDVNFVGSGEVLE VTTEPHPGDISIRIDKDNRLISEEYYRALPSTYTIQRL GKCKDKQLVITFDDGPDSRWTPTVLSTLKKYNVPAAFF MVGLQMEKNLPLVKQVYEDGHTIGNHTFTHHNMIENSD RRSYAELKLTRMLIESVTGHSTILFRAPYNADADPTEH EEIWPMIVASRRNYLFVGESIDPNDWEPNVTSDQIYQR VIDGVHHEDGHIILLHDAGGSSRKPTLDALPRIIETLQ HEGYQFISLEQYLGMGKQTLMPEINKGKAYYAMQTNLW LAEMIYHVSDFLTALFLVFLALGMMRLIFMYVLMIREK RAENRRNYAPIDAATAPAVSIIVPGYNEEVNIVRTITT LKQQDYPNLHIYFVDDGSKDHTLERVHEAFDNDDTVTI LAKKNGGKASALNYGIAACRSEYVVCIDADTQLKNDAV SRLMKHFIADTEKRVGAVAGNVKVGNQRNMLTYWQAIE YTSSQNFDRMAYSNINAITVVPGAIGAFRKEVIEAVGG FTTDTLAEDCDLTMSINEHGYIIENENYAVALTEAPET LRQFVKQRIRWCFGVMQAFWKHRSSLFAPSKKGFGLWA MPNMLIFQYIIPTFSPLADVLMLIGLFTGNALQIFFYY LIFLVIDASVSIMAYIFEGERLWVLLWVIPQRFFYRWI MYYVLFKSYLKAIKGELQTWGVLKRTGHVKG 57 Cell_division_ O34876 MAKKRNKARSRHSLQVVTLCISTAMVLMLIGIVVLTGF protein_FtsX TSRNLSSYVKENLTITMILQPDMNTEESAALCERIRTL HYINSLNFISKEQALKDGTKELGANPAEFAGENPFTGE IEVQLKANYANNDSIRNIVQQLRTYRGVSDITYPQSLV ESVNQTLGKISLVLLVIAVLLTIISFSLINNTIRLSIY AHRFSIHTMKLVGGSWSFIRAPFLRRAVLEGLVSALLA IAVLGIGICLLYEKEPEITKLLSWDALIITAIVMLAFG VIIATFCAWLSVNKFLRMKAGDLYKI 58 UDP-2,3- P44046 MKNIYFLSDAHLGSLAIDHRRTHERRLVRFLDSIKHKA diacylglucosamine_ AAVYLLGDMFDFWNEYKYVVPKGFTRFLGKISELTDMG hydrolase VEVHFFTGNHDLWTYGYLEKECGVILHRKPITTEIYDK VFYLAHGDGLGDPDPMFRFLRKVFHNRFCQRLLNFFHP WWGMQLGLNWAKRSRLKRKDGKEVPYLGEDKEYLVQYT KEYMSTHKDIDYYIYGHRHIELDLTLSRKARLLILGDW IWQFTYAVFDGEHMFLEEYVEGESKP 59 Poly-beta-1,6-N- P75905 MVGLDVLCYFIHAKGREKECYFERIIYQITCHSRTKCY acetyl-D- LCNIMKYSIIVPVFNRPDEVEELLESLLSQEEKDFEVV glucosamine_ IVEDGSQIPCKEVCDKYADKLDLHYYSKENSGPGQSRN synthase YGAERAKGEYLLILDSDVVLPKGYICAVSEELKREPAD AFGGPDCAHESFTDTQKAISYSMTSFFTTGGIRGGKKK LDKFYPRSFNMGIRRDVYQELGGFSKMRFGEDIDFSIR IFKAGKRCRLFPEAWVWHKRRTDFRKFWKQVYNSGIAR INLYKKYPESLKLVHLLPMVFTVGTALLVLMILFGLFL QLFPIINVFGSVFIMMGLMPLVLYSVIICVDSTMQNNS LNIGLLSIEAAFIQLTGYGCGFISAWWKRCVCGMDEFA AYEKNFYK 60 Enolase Q8DTS9 MKIEKVHAREIMDSRGNPTVEVEVTLENGVMGRASVPS GASTGENEALELRDGDKNRFLGKGVLKAVENVNNLIAP ALKGDCVLNQRAIDYKMLELDGTPTKSKLGANAILGVS LAVAQAAAKALNIPLYRYIGGANTYVLPVPMMNIINGG AHSDAPIAFQEFMIRPVGAPSEKEGIRMGAEVFHALAK LLKKRGLSTAVGDEGGFAPKFDGIEDALDSIIQAIKDA GYEPGKDVKIAMDCAASEFAVCEDGKWFYDYRQLKNGM PKDPNGKKLSADEQIAYLEHLITKYPIDSIEDGLDEND WENWVKLTSAIGDRCQLVGDDLFVTNVKFLEKGIKMGA ANSILIKVNQIGSLTETLEAIEMAHRHGYTTVTSHRSG ETEDTTIADIAVATNSGQIKTGSMSRTDRMAKYNQLIR IEEELGACAKYGYAKLK 61 Outer_membrane_ Q8G0Y6 MKKLFTIAMLLGVTLGIHAQEVYSLQKCRELALQNNRQ efflux_protein_ LKVSRMTVDVAENTRKAAKTKYLPRVDALAGYQHFSRE Bepc ISLLSDDQKNAFSNLGTNTFGQLGGQIGQNLTSLAQQG ILSPQMAQQLGQLFSNVATPLTQVGNNIGQSINDAFRS NTKNVYAGGIVVNQPIYMGGAIKAANDMAAIGEQVAQN NISLKRQLVLYGVDNAYWLAISLKKKEALAIRYRDLAQ KLNEDVKKMIREGVATRADGLKVEVAVNTADMQIARIQ SGVSLAKMALCELCGLELNGDIPLSDEGDADLPPTPST QFDNYTVSSSDTTGLNEARPELRLLQNAVDLSIQNTKL IRSLYMPHVLLTAGYSVSNPNLFNGFQKRFTDLWNIGI TVQVPVWNWGENKYKVRASKTATTIAQLEMDDVRKKID LEIEQNRLRLKDANKQLATSQKNMAAAEENLRCANVGF KEGVMTVTEVMAAQTAWQTSRMAIIDAEISVKLAQTGL QKALGGL 62 Phosphoethanol- Q7CPC0 MKRTFVTKMVKPIEENSLFFMFMLLVGAFTNVSHRNVF amine_transferase_ GYIELIADVYIICFLLSLCQRTIRQGLVIMLSSVIYVV CptA AIIDTCCKTLFDTPITPTMLLLAQETTGREATEFFLQY LNLKLFFSAADIILFLAFCHIVMAVKKMKFSTSYLKQP FVAFVLMFTIFVGMALSIYDKVQLYTVKNLSGLEVAVT NGFAHLYHPVERIVYGLYSNHLIAKQVDGVIMANQQIK VDSCSFTSPTIVLVIGESANRHHSQLYGYPLPTTPYQL AMKNGKDSLAVFTNVVSPWNLTSKVFKQIFSLQSVDEK GDWSKYVLFPAVFKKAGYHVSFLSNQFPYGINYTPDWT NNLVGGFFLNHPQLNKQMFDYRNVTIHNYDEDLLNDYK EIISYKKPQLIIFHLLGQHFQYSLRCKSNMKKFGIKDY KRMDLTDKEKQTIADYDNATLYNDFVLNKIVEQFRNKD AIIVYLSDHGEDCYGKDVNMAGRLTEVEQINLKKYHEE FEIPFWIWCSPIYKQRHRKIFTETLMARNNKFMTDDLP HLLLYLAGIKTKDYCEERNVISPSFNNNRRRLVLKTID YDKALYQ 63 Dipeptide_and_ P36837 MFKNHPKGLLQAAFSNMGERFGYYIMNAVLALFLCSKF tripeptide_ GLSDETSGLIASLFLAAIYVMSLVGGVIADRTQNYQRT permease_B IESGLVVMALGYVALSIPVLATPENNSYLLAFTIFALV LIAVGNGLFKGNLQAIVGQMYDDFETEAAKVSPERLKW AQGQRDAGFQIFYVFINLGALAAPFIAPVLRSWWLGRN GLTYDAALPQLCHKYINGTIGDNLGNLQELATKVGGNS ADLASFCPHYLDVFNTGVHYSFIASVVTMLISLIIFMS SKKLFPMPGKKEQIVNVEYTDEEKASMAKEIKQRMYAL FAVLGISVFFWFSFHQNGQSLSFFARDFVNTDSVAPEI WQAVNPFFVISLTPLIMWVFAYFTKKGKPISTPRKIAY GMGIAGFAYLFLMGFSLVHNYPSAEQFTSLEPAVRATM KAGPMILILTYFFLTVAELFISPLGLSFVSKVAPKNLQ GLCQGLWLGATAVGNGFLWIGPLMYNKWSIWTCWLVFA IVCFISMVVMFGMVKWLERVTKS 64 C4- Q9I4F5 MQKKIKIGLLPRVIIAILLGLFLGYYLPDPAVRVFLTF dicarboxylate_ NSIFSQFLGFMIPLIIIGLVTPAIAGIGKGAGKLLLAT transport_ VAIAYVDTIVAGGLSYGTGTWLFPSMIASTGGAIPHID protein_2 KATELTPYFTINIPAMVDVMSSLVFSFIAGLGIAYGGL RTMENLFNEFKTVIEKVIEKAIIPLLPLYIFGVFLSMT HNGQARQVLLVFSQIIIVILVLHVLILIYEFCIAGAIV KHNPFRLLWNMLPAYLTALGTSSSAATIPVTLKQTVKN GVSEEVAGFVVPLCATIHLSGSAMKITACALTICMLTD LPHDPGLFIYFILMLAIIMVAAPGVPGGAIMAALAPLS SILGFNEEAQALMIALYIAMDSFGTACNVTGDGAIALA VNKFFGKKKETSILS 65 Inner_membrane_ P76090 MISVYSIKPQFQRVLTPILELLHRAKVTANQITLWACV protein_YnbA LSLVIGILFWFAGDVGTWLYLCLPVGLLIRMALNALDG MMARRYNQITRKGELLNEVGDVVSDTIIYFPLLKYHPE SLYFIVAFIALSIINEYAGVMGKVLSAERRYDGPMGKS DRAFVLGLYGVVCLFGINLSGYSVYIFGVIDLLLVLST WIRIKKTLKVTRNSQTPE 66 2′,3′-cyclic- P08331 MKLSTILLSIMLGLSSSTMAQQKDVTIKLIETTDVHGS nucleotide FFPYDFITRKPKSGSMARVYTLVEELRKKDGKDNVYLL DNGDILQGQPISYYYNYVAPEKTNIAASVLNYMGYDVA TVGNHDIETGHKVYDKWFKELKFPILGANIIDTKTNKP YILPYYTIKKKNGIKVCVIGMLTPAIPNWLKESIWSGL RFEEMVSCAKRTMAEVKTQEKPDVIVGLFHSGWDGGIK TPEYDEDASKKVAKEVPGFDIVFFGHDHTPHSSIEKNI VGKDVICLDPANNAQRVAIATLTLRPKTVKGKRQYTVT KATGELVDVKELKADDAFIQHFQPEIDAVKAWSDQVIG RFENTIYSKDSYFGNSAFNDLILNLELEITKADIAFNA PLLFNASIKAGPITVADMFNLYKYENNLCTMRLTGKEI RKHLEMSYDLWCNTMKSPEDHLLLLSSTQNDAQRLGFK NFSFNFDSAAGIDYEVDVTKPDGQKVRILRMSNGEPFD ENKWYTVAVNSYRANGGGELLTKGAGIPRDSLKSRIIW ESPKDQRHYLMEEIKKAGVMNPQPNHNWKFIPETWTVP AAARDRKLLFGE 67 Fe(2+)_ P33650 MKLSELKTGETGVIVKVSGHGGFRKRIIEMGFIKGKTV transporter_FeoB EVLLNAPLQDPVKYKIMGYEVSLRHSEADQIEVLSDVK THSVGNEEEQEDNQLEMDSTTYDSTDKELTPEKQSDAV RRKNHTINVALVGNPNCGKTSLFNFASGAHERVGNYSG VTVDAKVGRAEFDGYVFNLVDLPGTYSLSAYSPEELYV RKQLVDKTPDVVINVIDSSNLERNLYLTTQLIDMHIRM VCALNMFDETEQRGDHIDAQKLSELFGVPMIPTVFTNG RGVKELFRQIIAVYEGKEDESLQFRHIHINHGHEIENG IKEMQEHLKKYPELCHRYSTRYLAIKLLEHDKDVEQLV SPLGDSIEIFNHRDTAAARVKEETGNDSETAIMDAKYG FINGALKEANFSTGDKKDTYQTTHVIDHVLTNKYFGFP IFFLVLLVMFTATFVIGQYPMDWIEAGVGWLGEFISKN MPAGPVKDMIVDGIIGGVGAVIVFLPQILILYFFISYM EDCGYMSRAAFIMDRLMHKMGLHGKSFIPLIMGFGCNV PAVMATRTIESRRSRLITMLILPLMSCSARLPIYVMIT GSFFALKYRSLAMLSLYIIGVLMAVAMSRLFSAFVVKG EDTPFVMELPPYRFPTWKAIGRHTWEKGKQYLKKMGGI ILVASIIVWALGYFPLPDDPNMDNQARQEQSYIGRIGK AVEPVFRPQGFNWKLDVGLLSGMGAKEIVASTMGVLYS NDGSFSDDNGYSSETGKYSKLHNLITKDVATMHHISYE EAEPIATLTAFSFLLFVLLYFPCVATIAAIKGETGSWG WALFAAGYTTALAWIVSAVVFQVGMLFM 68 UDP-N- P9WJM1 MESFIIEGGHQLSGTIAPQGAKNEALEVICATLLTSEE acetylglucosamine VIIRNVPDILDVNNLIKLLQDIGVKVKKLAPNEFSFQA DEVNLDYLESSDFVKKCSSLRGSVLMIGPLLGRFGKAT IAKPGGDKIGRRRLDTHFLGFKNLGAHFGRVEDRDVYE IQADKLVGTYMLLDEASITGTANIIMAAVLAEGTTTIY NAACEPYIQQLCKMLNAMGAKISGIASNLITIEGVKEL HSADHRILPDMIEVGSFIGIAAMIGDGVRIKDVSVPNL GLILDTFHRLGVQIIVDNDDLIIPRQDHYVIDSFIDGT IMTISDAPWPGLTPDLISVLLVVATQAQGSVLFHQKMF ESRLFFVDKLIDMGAQIILCDPHRAVVVGHDNAKKLRA GRMSSPDIRAGIALLIAALTAQGTSRIDNIVQIDRGYE NIEGRLNALGAKIQRAEVC 69 Ribitol-5- Q8RKI9 MNIAVIFAGGSGLRMHTKSRPKQFLDLNGKPIIIYTLE phosphate_cytidyl- LFDNHPNIDAIVVACIESWIPFLEKQLRKFEINKVVKI yltransferase IPGGKSGQESIYKGLCAAEEYAQSKGVSNEETTVLIHD GVRPLITEETITDNIKKVEEVGSCITCIPATETLIVKQ ADDALEIPSRADSFIARAPQSFRLIDIITAHRRSLAEG KADFIDSCTMMSHYGYKLGTIIGPMENIKITTPTDFFV LRAMVKVHEDQQIFGL

    [0104] In some embodiments, the Prevotella bacteria are from a strain of Prevotella bacteria comprising one or more of the proteins listed in Table 1 and that is free or substantially free of one or more proteins listed in Table 2. In some embodiments, the Prevotella bacteria are from a strain of Prevotella bacteria that comprises all of the proteins listed in Table 1 and/or all of the genes encoding the proteins listed in Table 1 and that is free of all of the proteins listed in Table 2 and/or all of the genes encoding the proteins listed in Table 2.

    Stabilizer and Bacterial Compositions

    [0105] In some aspects, provided herein is a stabilizer that stabilizes bacterial compositions comprises sucrose. In some embodiments, the stabilizer comprises about 100 g/kg, about 110 g/kg, about 120 g/kg, about 130 g/kg, about 140 g/kg, about 150 g/kg, about 160 g/kg, about 170 g/kg, about 180 g/kg, about 190 g/kg, about 200 g/kg, about 210 g/kg, about 220 g/kg, about 230 g/kg, about 240 g/kg, about 250 g/kg, about 260 g/kg, about 270 g/kg, about 280 g/kg, about 290 g/kg, or about 300 g/kg sucrose. In some embodiments, the stabilizer comprises at least 100 g/kg, at least 110 g/kg, at least 120 g/kg, at least 130 g/kg, at least 140 g/kg, at least 150 g/kg, at least 160 g/kg, at least 170 g/kg, at least 180 g/kg, at least 190 g/kg, at least 200 g/kg, at least 210 g/kg, at least 220 g/kg, at least 230 g/kg, at least 240 g/kg, at least 250 g/kg, at least 260 g/kg, at least 270 g/kg, at least 280 g/kg, at least 290 g/kg, or at least 300 g/kg sucrose.

    [0106] In some embodiments, the stabilizer comprises dextran 40k. In some embodiments, the stabilizer comprises about 100 g/kg, about 110 g/kg, about 120 g/kg, about 130 g/kg, about 140 g/kg, about 150 g/kg, about 160 g/kg, about 170 g/kg, about 180 g/kg, about 190 g/kg, about 200 g/kg, about 210 g/kg, about 220 g/kg, about 230 g/kg, about 240 g/kg, about 250 g/kg, about 260 g/kg, about 270 g/kg, about 280 g/kg, about 290 g/kg, or about 300 g/kg dextran 40k. In some embodiments, the stabilizer comprises at least 100 g/kg, at least 110 g/kg, at least 120 g/kg, at least 130 g/kg, at least 140 g/kg, at least 150 g/kg, at least 160 g/kg, at least 170 g/kg, at least 180 g/kg, at least 190 g/kg, at least 200 g/kg, at least 210 g/kg, at least 220 g/kg, at least 230 g/kg, at least 240 g/kg, at least 250 g/kg, at least 260 g/kg, at least 270 g/kg, at least 280 g/kg, at least 290 g/kg, or at least 300 g/kg dextran 40k.

    [0107] In some embodiments, the stabilizer comprises cysteine HCl. In some embodiments, the stabilizer comprises about 1.0 g/kg, about 1.1 g/kg, about 1.2 g/kg, about 1.3 g/kg, about 1.4 g/kg, about 1.5 g/kg, about 1.6 g/kg, about 1.7 g/kg, about 1.8 g/kg, about 1.9 g/kg, about 2.0 g/kg, about 2.1 g/kg, about 2.2 g/kg, about 2.3 g/kg, about 2.4 g/kg, about 2.5 g/kg, about 2.6 g/kg, about 2.7 g/kg, about 2.8 g/kg, about 2.9 g/kg, about 3.0 g/kg, about 3.1 g/kg, about 3.2 g/kg, about 3.3 g/kg, about 3.4 g/kg, about 3.5 g/kg, about 3.6 g/kg, about 3.7 g/kg, about 3.8 g/kg, about 3.9 g/kg, about 4.0 g/kg, about 4.1 g/kg, about 4.2 g/kg, about 4.3 g/kg, about 4.4 g/kg, about 4.5 g/kg, about 4.6 g/kg, about 4.7 g/kg, about 4.8 g/kg, about 4.9 g/kg, or about 5.0 g/kg cysteine HCl. In some embodiments, the stabilizer comprises at least 1.0 g/kg, at least 1.1 g/kg, at least 1.2 g/kg, at least 1.3 g/kg, at least 1.4 g/kg, at least 1.5 g/kg, at least 1.6 g/kg, at least 1.7 g/kg, at least 1.8 g/kg, at least 1.9 g/kg, at least 2.0 g/kg, at least 2.1 g/kg, at least 2.2 g/kg, at least 2.3 g/kg, at least 2.4 g/kg, at least 2.5 g/kg, at least 2.6 g/kg, at least 2.7 g/kg, at least 2.8 g/kg, at least 2.9 g/kg, at least 3.0 g/kg, at least 3.1 g/kg, at least 3.2 g/kg, at least 3.3 g/kg, at least 3.4 g/kg, at least 3.5 g/kg, at least 3.6 g/kg, at least 3.7 g/kg, at least 3.8 g/kg, at least 3.9 g/kg, at least 4.0 g/kg, at least 4.1 g/kg, at least 4.2 g/kg, at least 4.3 g/kg, at least 4.4 g/kg, at least 4.5 g/kg, at least 4.6 g/kg, at least 4.7 g/kg, at least 4.8 g/kg, at least 4.9 g/kg, or at least 5.0 g/kg cysteine HCl.

    [0108] In certain embodiments, the stabilizer is in liquid suspension. In some embodiments, the components of the stabilizer are dissolved in water to prepare the liquid suspension. In some such embodiments, the stabilizer comprises about 500 g/kg, about 510 g/kg, about 520 g/kg, about 530 g/kg, about 540 g/kg, about 550 g/kg, about 560 g/kg, about 570 g/kg, about 580 g/kg, about 590 g/kg, about 600 g/kg, about 610 g/kg, about 620 g/kg, about 630 g/kg, about 640 g/kg, about 650 g/kg, about 660 g/kg, about 670 g/kg, about 680 g/kg, about 690 g/kg, or about 700 g/kg water. In some such embodiments, the stabilizer comprises at least 500 g/kg, at least 510 g/kg, at least 520 g/kg, at least 530 g/kg, at least 540 g/kg, at least 550 g/kg, at least 560 g/kg, at least 570 g/kg, at least 580 g/kg, at least 590 g/kg, at least 600 g/kg, at least 610 g/kg, at least 620 g/kg, at least 630 g/kg, at least 640 g/kg, at least 650 g/kg, at least 660 g/kg, at least 670 g/kg, at least 680 g/kg, at least 690 g/kg, or at least 700 g/kg water.

    [0109] In some embodiments, the stabilizer comprises sucrose, dextran 40k, cysteine HCl, and water. In some such embodiments, the stabilizer comprises 150 g/kg to 250 g/kg sucrose. In some embodiments, the stabilizer comprises 200 g/kg sucrose. In some embodiments, the stabilizer comprises 150 g/kg to 250 g/kg dextran 40k. In some embodiments, the stabilizer comprises 200 g/kg dextran 40 k. In some embodiments, the stabilizer comprises 2 g/kg to 6 g/kg cysteine HCl. In some embodiments, the stabilizer comprises 4 g/kg cysteine HCl. In some embodiments, the stabilizer comprises the stabilizer comprises 500 g/kg to 700 g/kg water. In some embodiments, the stabilizer comprises 596 g/kg water. In some embodiments, the stabilizer comprises 200 g/kg sucrose, 200 g/kg dextran 40k, 4 g/kg cysteine HCl, and 596 g/kg water.

    [0110] In some aspects, provided herein are bacterial compositions comprising a stabilizer and bacteria, and methods of preparing same. In certain embodiments, the bacterial composition is prepared by combining bacteria with a certain percentage of the stabilizer in liquid suspension. In some embodiments, the percentage of the stabilizer solution combined with bacteria is about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%. In some embodiments, the percentage of the stabilizer solution combined with bacteria is at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, or at least 50%.

    [0111] In certain aspects, the bacterial compositions provided herein comprise a stabilizer. In some embodiments, the bacterial composition comprises sucrose. In some embodiments, the concentration of sucrose in the bacterial composition is about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%. In some embodiments, the concentration of sucrose in the bacterial composition is at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0%, at least 1.1%, at least 1.2%, at least 1.3%, at least 1.4%, at least 1.5%, at least 1.6%, at least 1.7%, at least 1.8%, at least 1.9%, at least 2.0%, at least 2.1%, at least 2.2%, at least 2.3%, at least 2.4%, at least 2.5%, at least 2.6%, at least 2.7%, at least 2.8%, at least 2.9%, or at least 3.0%.

    [0112] In some embodiments, the bacterial composition comprises dextran 40k. In some embodiments, the concentration of dextran 40k in the bacterial composition is about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%. In some embodiments, the concentration of dextran 40k in the bacterial composition is at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0%, at least 1.1%, at least 1.2%, at least 1.3%, at least 1.4%, at least 1.5%, at least 1.6%, at least 1.7%, at least 1.8%, at least 1.9%, at least 2.0%, at least 2.1%, at least 2.2%, at least 2.3%, at least 2.4%, at least 2.5%, at least 2.6%, at least 2.7%, at least 2.8%, at least 2.9%, or at least 3.0%.

    [0113] In some embodiments, the bacterial composition comprises cysteine HCl. In some embodiments, the concentration of cysteine HCl in the bacterial composition is about 0.001%, about 0.005%, about 0.01%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about 0.018%, about 0.019%, about 0.02%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.025%, about 0.026%, about 0.027%, about 0.028%, about 0.029%, about 0.03%, about 0.031%, about 0.032%, about 0.033%, about 0.034%, about 0.035%, about 0.036%, about 0.037%, about 0.038%, about 0.039%, about 0.04%, about 0.041%, about 0.042%, about 0.042%, about 0.043%, about 0.044%, about 0.045%, about 0.046%, about 0.047%, about 0.048%, about 0.049%, or about 0.05%. In some embodiments, the concentration of cysteine HCl in the bacterial composition is at least 0.001%, at least 0.005%, at least 0.01%, at least 0.011%, at least 0.012%, at least 0.013%, at least 0.014%, at least 0.015%, at least 0.016%, at least 0.017%, at least 0.018%, at least 0.019%, at least 0.02%, at least 0.021%, at least 0.022%, at least 0.023%, at least 0.024%, at least 0.025%, at least 0.026%, at least 0.027%, at least 0.028%, at least 0.029%, at least 0.03%, at least 0.031%, at least 0.032%, at least 0.033%, at least 0.034%, at least 0.035%, at least 0.036%, at least 0.037%, at least 0.038%, at least 0.039%, at least 0.04%, at least 0.041%, at least 0.042%, at least 0.042%, at least 0.043%, at least 0.044%, at least 0.045%, at least 0.046%, at least 0.047%, at least 0.048%, at least 0.049%, or at least 0.05%.

    [0114] In some embodiments, the bacterial composition comprises sucrose, dextran 40k, and cysteine HCl. In some such embodiments, the bacterial composition comprises 1% to 2% sucrose. In some embodiments, the bacterial composition comprises 1.5% sucrose. In some embodiments, the bacterial composition comprises 1% to 2% dextran 40k. In some embodiments, the bacterial composition comprises 1.5% dextran 40k. In some embodiments, the bacterial composition comprises 0.01% to 0.05% cysteine HCl. In some embodiments, the bacterial composition comprises 0.03% cysteine HCl. In some embodiments, the bacterial composition comprises 1.5% sucrose, 1.5% dextran 40k, and 0.03% cysteine HCl.

    [0115] In certain aspects, the bacterial composition comprises bacteria. In some embodiments, the bacteria are anaerobic bacteria. In some embodiments, the anaerobic bacteria are Prevotella histicola. In some such embodiments, the anaerobic bacteria are Prevotella histocola Strain B 50329.

    [0116] In some embodiments, the bacterial composition is lyophilized to form a powder.

    EXAMPLES

    Example 1: Exemplary Manufacturing Process of Prevotella histicola and Lyophilized Powder of Prevotella histicola and Stabilizer

    [0117] Exemplary manufacturing processes of Prevotella histicola are shown in FIG. 1 and FIG. 2. In this exemplary method, the anaerobic bacteria are grown in growth media comprising the components listed in Table 3. The media is filter sterilized prior to use.

    TABLE-US-00003 TABLE 3 Growth Media Component g/L Yeast Extract 19512 10 Soy Peptone A2SC 19649 12.5 Soy Peptone E110 19885 12.5 Dipotassium Phosphate K2HPO4 1.59 Monopotassium phosphate 0.91 L-Cysteine-HCl 0.5 Ammonium chloride 0.5 Glucidex 21 D (Maltodextrin) 25 Glucose 10 Hemoglobin 0.02

    [0118] Briefly, a 1 L bottle is inoculated with a 1 mL of a cell bank sample that had been stored at −80° C. This inoculated culture is incubated in an anaerobic chamber at 37° C., pH=6.5 due to sensitivity of this strain to aerobic conditions. When the bottle reaches log growth phase (after approximately 14 to 16 hours of growth), the culture is used to inoculate a 20 L bioreactor at 5% v/v. During log growth phase (after approximately 10 to 12 hours of growth), the culture is used to inoculate a 3500 L bioreactor at 0.5% v/v.

    [0119] Fermentation culture is continuously mixed with addition of a mixed gas at 0.02 VVM with a composition of 25% CO.sub.2 and 75% N.sub.2. pH is maintained at 6.5 with ammonium hydroxide and temperature controlled at 37° C. Harvest time is based on when stationary phase is reached (after approximately 12 to 14 hours of growth).

    [0120] Alternatively, the fermentation culture is continuously mixed with the addition of 100% CO.sub.2 gas at 0.002 VVM. pH is maintained at 6.5 with ammonium hydroxide and temperature controlled at 37° C. Harvest time is based on when stationary phase is reached (after approximately 12 to 14 hours of growth).

    [0121] Once fermentation is complete, the culture is cooled to 10° C., centrifuged, and the resulting cell paste is collected.

    [0122] A stabilizer is prepared by combining and mixing the components described in Table 4. In order to prepare a lyophilized powder of Prevotella histicola and the stabilizer, 10% stabilizer is added to the cell paste and mixed thoroughly (Stabilizer Concentration (in slurry): 1.5% Sucrose, 1.5% Dextran, 0.03% Cysteine). The cell slurry is lyophilized.

    TABLE-US-00004 TABLE 4 Stabilizer Formulation Component g/kg Sucrose 200 Dextran 40k 200 Cysteine HCl 4 Water 596

    Example 2: Effect of CO.SUB.2 .Availability on Prevotella histicola Growth

    [0123] The effect of CO.sub.2 availability on the growth of Prevotella histicola Strain B 50329 was tested. Prevotella histicola was cultured under anaerobic conditions with sparging of 95% N.sub.2 and 5% CO.sub.2 at a rate of either 0.1 volume of gas per volume of vessel per minute (vvm) or 0.02 vvm. As seen in FIG. 3, sparging an increased amount of the gas increased the growth potential of the Prevotella histicola.

    [0124] The Prevotella histicola strain was then cultured with sparging of pure N.sub.2 (0% CO.sub.2), 95% N.sub.2 and 5% CO.sub.2, or 75% N.sub.2 and 25% CO.sub.2 at a rate of 0.02 vvm. As can be seen in FIG. 4, the presence of CO.sub.2 is necessary for initiation of Prevotella histicola growth. Sparging increasing concentrations of CO.sub.2 increased the growth potential of the Prevotella histicola. Sparging 100% CO.sub.2 at a lower rate (0.005 vvm) resulted in an intermediate growth potential for the Prevotella histicola.

    [0125] At all scales, mass transfer of CO.sub.2 is important and determined by a variety of factors. Here we show the impact of scale, agitation, gas concentration, and gas flow rate (Table 5).

    TABLE-US-00005 TABLE 5 Prevotella histicola growth under various conditions CO.sub.2 Gas Final Final Scale Agitation Conc. flow rate OD TCC 15L 100 RPM  5% CO.sub.2   0.1vvm 14.22 1.1 × 10.sup.10 cells/mL 15L 100 RPM  5% CO.sub.2  0.02vvm 3 NA 15L 100 RPM 25% CO.sub.2  0.02vvm 11.7 7.16 × 10.sup.9 cells/mL 36L  50 RPM 25% CO.sub.2  0.02vvm 10.99 8.47 × 10.sup.9 cells/mL 50L 100 RPM 25% CO.sub.2  0.02vvm 30.1 3.77 × 10.sup.10 cells/mL 50L  60 RPM 75% CO.sub.2 0.007vvm 32 NA 36L  70 RPM 25% CO.sub.2  0.02vvm 29 2.33 × 10.sup.10 cells/mL 36L  70 RPM 25% CO.sub.2  0.02vvm 34.4 2.82 × 10.sup.10 cells/mL 36L  70 RPM 25% CO.sub.2  0.02vvm 33.8 2.47 × 10.sup.10 cells/mL

    [0126] The Prevotella histicola was consuming CO.sub.2 during growth. As seen in FIG. 5, when CO.sub.2 was added to a freshly inoculated culture of Prevotella histicola, the CO.sub.2 concentration increased and the concentration approached equilibrium. As the Prevotella histicola culture grew, the increase of CO.sub.2 concentration slowed and then, as the culture entered logarithmic growth, the level of CO.sub.2 declined. When the culture stopped logarithmic growth, this decline stopped as mass transfer offset consumption. When the sparging of the CO.sub.2 was turned off, the concentration of CO.sub.2 in the culture began to immediately to rapidly decline, indicating that that Prevotella histicola consumed CO.sub.2. If no consumption were to occur, such as in sterile media, little to no change of CO.sub.2 concentration would be observed in that time frame.

    Example 3: Maltodextrin in Combination with Glucose can Support Growth of Prevotella histicola Strain B 50329 Better than Glucose Alone as Sugar Source

    [0127] The results in FIG. 6 show that, at the same amount of total sugar, maltodextrin (25 g/L) in combination with glucose (10 g/L), compared to glucose (35 g/L) alone, led to increased process yield. Other than the sugars used, the culture conditions were identical. The result show that for equivalent masses of glucose and maltodextrin, Prevotella histicola Strain B 50329 grows better on maltodextrin plus glucose than on glucose alone. Because maltodextrin is just chains of glucose monomers, the results suggest that the cells may be benefiting in growth from some aspect of the chain structure.

    INCORPORATION BY REFERENCE

    [0128] All publications patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

    EQUIVALENTS

    [0129] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.